Deployment, Post-Traumatic Stress Disorder and Hypertensive Disorders of Pregnancy among U.S. Active-Duty Military Women by Nash, Michelle C.
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
June 2017
Deployment, Post-Traumatic Stress Disorder and
Hypertensive Disorders of Pregnancy among U.S.
Active-Duty Military Women
Michelle C. Nash
University of South Florida, michellecnash1@gmail.com
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the Epidemiology Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Nash, Michelle C., "Deployment, Post-Traumatic Stress Disorder and Hypertensive Disorders of Pregnancy among U.S. Active-Duty
Military Women" (2017). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/6914
 
 
 
 
 
 
 
 
Deployment, Post-Traumatic Stress Disorder and Hypertensive Disorders of Pregnancy among 
 
U.S. Active-Duty Military Women 
 
 
 
by 
 
 
 
Michelle C. Nash 
 
 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
with a concentration in Epidemiology 
Department of Epidemiology and Biostatistics 
College of Public Health 
University of South Florida 
 
 
Major Professor: Kathleen O’Rourke, Ph.D. 
Kevin Kip, Ph.D. 
Wei Wang, Ph.D. 
Michael Custer, Dr.PH 
 
 
Date of Approval: 
May 15, 2017 
 
 
 
Keywords: Perinatal Health, Maternal and Child Health, Birth Outcomes, Mental Health, War  
 
Copyright © 2017, Michelle C. Nash
i 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
List of Tables       iii 
 
List of Figures      vi 
 
Abstract       vii 
 
Chapter 1: Introduction     1 
 
Chapter 2: Literature Review    4 
 Hypertensive Disorders of Pregnancy  4 
 Deployment and Adverse Birth Outcomes  6 
 Deployment Characteristics and Perinatal Health  8 
 Post-Traumatic Stress Disorder (PTSD)  10 
 
Chapter 3: Methods      18 
 Overview of Study Population   18 
 Outcome Definition     20 
 Analysis Dataset Merge    21 
 Potential Confounders and Covariates  22 
 Specific Aim 1 Deployment Measures  23 
  Deployment Definition   23 
  Previous Research    24 
  Deployment Measures   24 
  Statistical Modeling    25 
   Sub-Analysis: Stratification by Race  26 
   Sub-Analysis: HDP Types  26 
   Sub-Analysis: Timing of Conception  26 
   Sub-Analysis: Military Entry Timing  27 
 Specific Aim 2 Deployment Exposures  27 
  Deployment Measures   27 
  Statistical Methods    28 
 Specific Aim 3 PTSD Exposures   29 
  Exposure Definition    29 
   Mini-Sensitivity Analysis  31 
  Statistical Modeling    32 
   Analysis 1: Overall Cohort  32 
    Sub-Analysis: Effect Modification by Deployment  32 
    Sub-Analysis: Stratification by Race  32 
    Sub-Analysis: HDP Types  32 
   Analysis 2: PDHA Mothers  33 
    Sub-Analysis: Stratification by Race  33 
    Sub-Analysis: HDP Types  33 
    Sub-Analysis: Timing of Conception  33 
ii 
 
     
    Sub-Analysis: Pre-Post Comparison  33 
    Sub-Analysis: PDHRA Mothers Only  34 
 
 
Chapter 4: Results      35 
 Overall Cohort     35 
 Specific Aim 1 Deployment    36 
  Descriptive Characteristics   36 
  Overall Findings    37 
  Racial/Ethnic Findings   38 
  Other Sub-Analysis Findings   39 
 Specific Aim 2 Classification Trees   40 
  Descriptive Characteristics   40 
  Classification Tree Findings   40 
 Specific Aim 3 PTSD     41 
  Descriptive Characteristics: PTSD among the Entire Cohort  41 
  Descriptive Characteristics: PDHA Mothers  41 
  Descriptive Characteristics: PTSD among PDHA Mothers  42 
  Overall Findings    43 
  Overall Sub-Analysis Findings  44 
  Overall Findings: PDHA Mothers  44 
  Racial/Ethnic Findings: PDHA Mothers  45 
  HDP Sub-Type Findings: PDHA Mothers  46 
  PDHRA Agreement Sub-Analysis Findings: PDHA Mothers  46 
  Timing of Conception Sub-Analysis Findings: Entire Cohort and PDHA 
   Mothers      47 
 
Chapter 5: Discussion, Conclusions, and Recommendations  72 
 Deployment and HDP    72 
 PTSD and HDP     75 
 Overall Strengths and Weaknesses   79 
 Conclusions and Future Research   80 
 
Chapter 6: References     81 
 
Appendix 1: ICD-9-CM Codes Used to Define Variables in the Methods Section  88 
 
Appendix 2: Main Terms and Variable Definitions Used in the Methods Section  90 
 
Appendix 3: Supplemental Tables for Results Section  95 
 
Appendix 4: USF IRB Letter for the Current Study  108 
 
About the Author      End Page 
   
 
 
 
 
 
iii 
 
 
 
 
 
 
 
LIST OF TABLES 
 
Table 1. PTSD-Specific Question on the PDHA/PDHRA according to DSM Criteria.  16 
 
Table 2. Frequency of Main Exposures and Covariates for the Entire Cohort, 
  n=36,6575.  48 
 
Table 3. Frequency of Main Exposures and Covariates by HDP Status for the Entire 
  Cohort, n=36,675.  49 
 
Table 4.  Frequency of HDP Sub-types Overall and by Race, Entire Cohort. 50 
 
Table 5.  Frequency of Main Exposures and Covariates, Specific Aim 1. 51 
 
Table 6.  Frequency of Main Deployment Exposures and Covariates by HDP Status, 
  Specific Aim 1. 53 
 
Table 7.  Odds-ratios and 95% Confidence Intervals for Overall Deployment Measures 
  and HDP, Specific Aim 1. 55 
 
Table 8.  Odds-ratios and 95% Confidence Intervals for Overall Deployment Measures 
  and HDP by Racial Category, Specific Aim 1. 56 
 
Table 9.  Frequency of Main Exposures and Covariates by HDP Status for Deployed 
  Women Only, Specific Aim 2. 57 
 
Table 10.  Odds-ratio and 95% Confidence Intervals for Categorized Cumulative Weeks 
  of Deployment among Deployed Women Only, Specific Aim 2, n=11,685. 59 
 
Table 11.  Frequency of PTSD Exposures for the Entire Cohort, Specific Aim 3, 
  n=36,675. 60 
 
Table 12.  Frequency of PTSD Exposures by HDP Status for the Entire Cohort, Specific 
  Aim 3, n=36,675. 61 
 
Table 13.  Frequency of Main Exposures and Covariates for PDHA Mothers Only, 
  Specific Aim 3, n=8,801. 62 
 
Table 14.  Frequency of Main Exposures and Covariates by HDP Status for PDHA 
  Mothers Only, Specific Aim 3, n=8,801. 64 
 
Table 15.  Frequency of HDP Sub-types Overall and by Race, PDHA Mothers Only, 
  Specific Aim 3. 66 
 
Table 16.  Frequency of PTSD for PDHA Mothers Only, Specific Aim 3, n=8,801. 67 
iv 
 
 
Table 17.  Frequency of PTSD by HDP Status for PDHA Mothers Only, Specific Aim 3, 
  n=8,801. 68 
 
Table 18.  Odds-ratio and 95% Confidence Intervals for PTSD, Entire Cohort, Specific 
  Aim 3, n=35,897. 69 
 
Table 19.  Odds-ratio and 95% Confidence Intervals for PTSD and HDP, Case- 
  Definition Based on Screening among PDHA Mothers Only, Specific  
  Aim 3. 70 
 
Table 20.  Odds-ratio and 95% Confidence Intervals for PTSD Diagnosis Relative to 
  Timing of Conception and HDP, Specific Aim 3. 71 
 
Table A1.1. ICD-9-CM Procedure Codes for Live-Born Singleton Infants. 88 
 
Table A1.2. ICD-9-CM Diagnosis Codes for HDP. 88 
 
Table A1.3. ICD-9-CM Diagnosis Codes for Pre-Gestational Diabetes. 88 
 
Table A1.4. ICD-9-CM Diagnosis Codes for Gestational Age. 89 
 
Table A2.1. Outcome Definition for Study. 90 
 
Table A2.2. Aim 1: Main Terms and Variable Definitions. 90 
 
Table A2.3. Aim 2: Main Terms and Variable Definitions. 91 
 
Table A2.4. Aim 3: Main Terms and Variable Definitions. 92 
 
Table A2.5. Additional Covariates: Main Terms and Variable Definitions. 93 
 
Table A3.1. Odds-ratio and 95% Confidence Intervals for Deployed vs. Non-Deployed, 
  HDP Sub-Types. 95 
 
Table A3.2. Odds-ratio and 95% Confidence Intervals for Timing of Deployment End 
   Relative to Birth, HDP Sub-Types. 96 
 
Table A3.3. Odds-ratio and 95% Confidence Intervals for Cumulative Weeks of  
  Deployment among Deployed Women Only, HDP Sub-Types. 98 
 
Table A3.4. Frequency of Main Exposures and Covariates by HDP Status for PDHA 
   Moms Missing PTSD/Probable Responses Only. 100 
 
Table A3.5. Odds-ratio and 95% Confidence Intervals for Any PTSD vs. None, Racial  
  Groups. 103 
 
Table A3.6. Odds-ratio and 95% Confidence Intervals for Any PTSD and HDP Sub- 
  Types, Entire Cohort. 104 
 
 
v 
 
Table A3.7. Odds-ratio and 95% Confidence Intervals for PTSD and HDP, Case- 
  Definition Based on Screening among PDHRA Moms Only. 105 
 
Table A3.8. Odds-ratio and 95% Confidence Intervals for PTSD and HDP Sub-types, 
   Case-Definition Based on Screening among PDHA Moms Only. 106 
 
Table A3.9. Odds-ratio and 95% Confidence Intervals for Pre-Post Agreement Between 
   PDHA and PDHRA PTSD Screening and HDP. 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
 
 
 
 
LIST OF FIGURES 
 
 
Figure 1. DSM-V Criteria and Symptoms for PTSD. 11  
 
Figure 2.  Classification Tree for Cumulative Weeks of Deployment by Maternal Age.  58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
 
 
 
 
ABSTRACT 
 
Introduction. Today women comprise 15% of the U.S. active-duty military, but are often 
overlooked in research of the Armed Forces.  While some of the challenges faced by women 
are similar to men, they encounter unique stressors related to childcare while deployed, sexual 
harassment and assault, and gynecological needs.  Women are also more likely than men to 
develop post-traumatic stress disorder (PTSD).  Both stress and PTSD have been linked to the 
development of chronic hypertension and some adverse birth outcomes.  We hypothesized that 
post-9/11/2001 era military women who deployed or who had indicators of PTSD would be at 
greater risk of developing a hypertensive disorder of pregnancy (HDP) than non-deployed or 
non-PTSD military women.   
Methods. We conducted a retrospective cohort study using a U.S. Department of Defense 
database comprised of all active-duty women who gave birth to their first, live-born singleton 
infant using Tricare from January 1, 2004 to December 31, 2008.  The database included 
maternal and infant birth hospitalization records, maternal mental health visits, and  
post-9/11/2001 deployment information which included Post-Deployment Health Assessment 
(PDHA) and Reassessment (PDHRA) screening responses.  HDP was defined with ICD-9-CM 
codes in the maternal birth hospitalization record. We evaluated the risk of HDP associated with 
overall deployment and timing of deployment ending compared to non-deployed women, in 
addition to cumulative months of deployment.  We also conducted Classification Tree Analysis 
(CART) to determine appropriate cut-points for categorization of deployment variables among 
mothers who deployed: cumulative weeks of deployment, percent of study time spent deployed, 
and dwell time between two most recent pre-birth deployments.  We explored effect modification 
by covariates postulated to potentially modify the relationship between deployment history and 
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risk of HDP.  New variables were defined and used in multivariable logistic regression models 
for each deployment measure.  Women fit into four PTSD case-definition categories: confirmed 
(ICD-9-CM diagnosis), probable (possible plus endorsement of “high risk” items on the PDHA), 
possible (endorsement of ≥3 PTSD items on the PDHA), or none (no PTSD indicators).  We 
compared mothers with PTSD to non-cases using multivariable logistic regression to quantify 
the risk of HDP, and repeated the analyses using a ≥2 PTSD item endorsement case-definition 
criteria.  All logistic regression models were adjusted for known confounders and important 
covariates.   
Results. There were a total of 36,675 births, 13.4% of mothers experienced at least one HDP, 
and 35% of mothers deployed.  No increased risk of HDP was observed for deployment overall 
(OR=1.02, 95% CI: 0.95-1.09), but black mothers who deployed were 13% more likely to 
develop an HDP (OR=1.13, 95% CI: 1.00-1.27).  CART revealed an important cut-point for 
cumulative deployment length of ≥1 year, which was statistically significant among mothers <35 
years old.  Mothers with ≥1 year cumulative deployment were 17% more likely to have an HDP 
than mothers deployed <1 year (OR=1.17, 95% CI: 1.01-1.36).  The prevalence of confirmed 
PTSD was 1.6% in the overall cohort.  The prevalence of any PTSD among deployed mothers 
who completed a PDHA was 6.2%.  Overall, PTSD was not significantly associated with HDP 
except among probable PTSD cases using the ≥2 item criteria (OR=1.30, 95% CI: 1.01-1.67) 
and among confirmed PTSD mothers identifying as “other” race (OR=6.62, 95% CI: 1.72-25.47).   
Conclusion. Results are suggestive of an elevated risk of HDP among the military population 
among women who deployed for a year or longer and for black mothers.  Although PTSD did 
not clearly confer additional risk in the overall cohort, there is evidence to support further 
research using more thorough screening especially across racial/ethnic groups.  Our study likely 
underestimated PTSD and possibly attenuated results since individuals may purposely report 
inaccurately on the PDHA in order to go home sooner after deployment.  Future studies should 
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include information related to deployment-specific experiences and screen all participants for 
evidence of PTSD. 
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CHAPTER 1 
Introduction 
 
 
Today women comprise 15% of the United States (U.S.) active-duty military,1 and the 
responsibilities of female military personnel are expected to shift since the Department of 
Defense (DOD) opened all military positions to women in 2016.2  It is possible that the burden of 
women developing long-term health consequences similar to men after combat will increase, 
including PTSD.  PTSD is a condition that develops in certain individuals after experiencing or 
witnessing a traumatic event.3 Symptoms can include intense flashbacks and social/emotional 
distancing that dramatically interferes with an individual’s daily activities.3  While the incidence is 
estimated to be approximately nine cases per 1,000 veterans (both sexes),4 a 2011 survey 
revealed that 42% of women and 35% of male veterans believed they experienced some 
symptoms of PTSD after military service.5  Psychological trauma can dysregulate stress 
response systems,6 and has been linked to chronic conditions such as cardiovascular disease7,8 
in addition to certain adverse birth outcomes.9  Women are more likely to develop PTSD after a 
traumatic event than men.10  With the growing proportion of females in the Armed Forces, their 
increasing likelihood of exposure to intense acts of war, and their unique medical and physical 
needs, PTSD has the potential to place an economic burden on both the U.S. military and 
civilian health care systems.   
 
Hypertensive disorders of pregnancy (HDP) are an increasingly important cause of maternal 
morbidity and mortality in the U.S., accounting for 16% of all perinatal-related deaths.11  
Research in the general population suggests women experience greater risk of HDP following 
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chronic stress,12 but the relationship has not been thoroughly explored among the military. 
Civilian epidemiologic studies of psychosocial stress reveal a higher chance of developing HDP 
among mothers reporting the most life strain prior to or during pregnancy.13-15  Other research 
examining birth outcomes following traumatic events (i.e. 9/11/2001, Hurricane Katrina) 
experienced by civilian mothers indicate an increased risk of low birth weight (LBW), preterm 
birth (PTB), and other adverse outcomes among the mothers with positive screening indicators 
of PTSD.16-18  However, few of these studies included HDP.  No analytical epidemiologic studies 
have been conducted examining the impact of PTSD on HDP risk among active-duty military 
mothers, but it has been shown that female service member veterans encounter a greater 
prevalence of HDP despite lower obesity rates than the general population.19,20  Overall the 
findings remain inconsistent due to differing methodologies.  Since active-duty women face a 
higher likelihood of encountering extremely distressing experiences and HDP can result in 
excess maternal mortality, it is imperative to understand the role of trauma in the development 
of HDP among the growing female military population.          
 
The overall objective of this project was to determine HDP risk among female military personnel 
who gave birth between 2004 and 2008.  We hypothesized that the likelihood of HDP would be 
higher among active-duty women with certain deployment characteristics or PTSD compared to 
active-duty women without these experiences.  To test our central hypothesis, we pursued 
these specific aims: 
1. Identify the effect of deployment to the Middle East between 2001 and 2008 on 
HDP incidence among active-duty women who gave birth, adjusted for known 
confounders. 
Hypothesis: Deployment, timing of its ending relative to birth, and cumulative 
deployment length will impact HDP incidence compared to non-deployed women or 
women with the shortest cumulative deployment length. 
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2. Explore which pre-birth dwell times (months off between deployments) and 
deployment durations are associated with the greatest risk of HDP among 
women deployed between 2001 and 2008 and who subsequently gave birth. 
Approach: We will identify 1) the cumulative number of deployed months, 2) the 
percent of study time spent deployed, 3) the number of weeks dwell time between 
the last two pre-birth deployments, and, 4) the ratio between the duration of the 
earlier two most recent deployments and dwell time afterwards that are associated 
with the greatest risk of HDP. 
  
3. Evaluate the association between PTSD and HDP among active-duty women 
deployed to the Middle East between 2003 and 2008, who subsequently gave 
birth adjusted for known confounders. 
Hypothesis: Women diagnosed with confirmed PTSD or who screen positive on post-
deployment health assessments prior to birth will experience a greater risk of HDP 
compared to women with no PTSD indicators.   
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CHAPTER 2 
Literature Review 
 
 
Hypertensive Disorders of Pregnancy 
Between 5-10% of pregnancies are impacted by HDP yearly, and the condition is responsible 
for 16% of maternal deaths in developed countries.  This figure reaches nearly 25% in some 
less developed areas of the world where ability to treat the condition is lacking.  The incidence 
of all HDP has increased in the U.S. over recent years, likely due to the increase in obesity and 
older maternal age at birth.  The biological pathways associated with HDP are not well 
understood, but are necessary to understand since mothers who experience HDP are at 
increased risk of cardiovascular disease later in life.21  Four different conditions comprise HDP: 
1) chronic hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg diagnosed before 20 weeks gestation or diagnosed after 20 weeks gestation and 
persisting >12 weeks postpartum), 2) gestational hypertension (systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg diagnosed before 20 weeks gestation that 
resolves ≤12 weeks postpartum), 3) preeclampsia (systolic blood pressure ≥140 mmHg or 
diastolic blood pressure ≥90 mmHg diagnosed after 20 weeks gestation with proteinuria) and, 4) 
preeclampsia superimposed on chronic hypertension.22  Preeclampsia is the most severe 
manifestation, effecting about 3% of pregnancies in the U.S. each year.  With improved early 
identification through screening, the rates of eclampsia decreased substantially in the U.S. 
during the 20th century.  Established HDP risk factors include family history of preeclampsia, 
primiparity, preeclampsia in a previous pregnancy, multiple gestation, maternal obesity, older 
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maternal age, maternal race, and pre-gestational diabetes.21,23  Maternal stress has also been 
hypothesized to contribute to HDP development.   
 
When the brain perceives a stimulus as potentially threatening, the hypothalamic-pituitary-
adrenal (HPA) axis is activated by releasing corticotropin-releasing hormone and arginine-
vasopressin by the hypothalamus.  These signal the pituitary gland to release cortisol and 
vasopressin (ADH) while the adrenal glands are signaled to release epinephrine.  ADH controls 
the amount of water that the kidneys retain in addition to having a role in blood pressure 
regulation.  When it is released as part of the normal physiological response to stress, it 
constricts the blood vessels to increase blood pressure.  The response is beneficial in acute 
situations; however, chronic health complications arise in the presence of ongoing stressors 
when the HPA axis remains activated.24,25  Continued exposure to stress has been shown to 
increase the risk of cardiovascular diseases,26 gastrointestinal conditions, and Type II 
diabetes,27 and a growing body of epidemiologic literature also reveals increased risk of LBW, 
PTB, and HDP following exposure to traumatic events or chronic stressors prior to or during 
pregnancy.9   
 
A multitude of situations and events encountered in daily life can act as stressful stimuli that 
activate the HPA axis.  For example, Walker et al.28 reported that pregnant women who later 
developed HDP had higher mean increase in blood pressure on days that they worked 
compared to working mothers who did not develop an HDP, but they did not explore perceived 
job strain.  Loss of a close relative between six months prior to conception to 12 weeks 
gestation resulted in a statistically significant increased risk of pre-eclampsia among Swedish 
mothers,13 while an Amsterdam study found a statistically non-significant elevated risk of HDP 
among mothers self-reporting the highest levels of work stress before 24 weeks gestation.15  
Non-response bias might explain their findings, as the most stressed mothers may have failed 
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to return their surveys.  Other single studies reported positive associations with HDP,14,29-31 with 
one being statistically non-significant.32  Each study used a different method of defining stress, 
in addition to differing exposure windows.  Two authors completed pooled analyses using some 
of these studies. Katz et al.33 included 161,000 pregnant women and found that physically 
stressful work was associated with a 60% increased risk of HDP (95% CI: 1.3-1.96).  A larger 
pooled analysis also revealed a positive association between mental stress (OR=1.26, 95% CI: 
1.0-1.59) and work stress (OR=1.40, 95% CI: 1.09-1.80) and HDP.12  The latter analysis 
included more heterogeneous studies than the former which could explain the differing 
magnitudes of association.   
 
Deployment and Adverse Birth Outcomes 
Deployment of active-duty military personnel to war zones poses unique medical and social 
challenges.  Both the service member and their families encounter emotional hurdles at each 
stage of deployment: preparing for separation prior to, worrying about the others’ safety during, 
and facing possible reintegration issues post-deployment.34  Many of these issues are gender 
neutral, but women experience specific difficulties surrounding their reproductive needs during 
and after deployment that must be addressed.  For example, the reality of sexual assault faced 
by women in conjunction with military service is beginning to be recognized publicly.  Individuals 
serving in active war zones are barred from having sexual relations due to the possibility of 
pregnancy and threats to morale; however, women are commonly subjected to sexual 
harassment and sexual abuse while deployed despite this rule.  In a 2014 DOD survey 
conducted by the RAND Corporation of the military workforce, just under 5% of active-duty 
women reported sexual assault in the preceding year.35  In a more recent 2017 survey of 1,339 
women who were in the military during Operation Enduring Freedom (OEF)/Operation Iraqi 
Freedom (OIF), 16% of participants reported being the victim of attempted or completed sexual 
assault during their service time.  Interestingly, sexual assault in a non-deployment setting was 
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associated with unethical behaviors demonstrated by leadership, and it is expected that similar 
patterns exist to facilitate assaults in deployed situations.36  Unintended pregnancies do result 
from this type of abuse, in addition to serious emotional disturbances requiring mental health 
services post-deployment.  Although the number of women conceiving during deployment is 
estimated to be 10%,37 the female active-duty population has a birth rate comparable to 
civilians.38  Unfortunately, war zones encompass an endless variety of mild to severe stressors 
with the potential to effect a service woman’s future health.  It is therefore necessary to 
understand their impact on pregnancy outcomes in this population. 
 
Few studies on the impact of stress and adverse birth outcomes have included the military 
population directly, and only one has examined HDP as an outcome.  Endara et al.39 examined 
PTB, LBW, and birth defects among military infants who were in utero during the 9/11/2001 
terrorist attacks compared to infants in utero during the same time in 2000.  The authors 
reported null findings, but the results included births to both active-duty women and spouses of 
active-duty men.  A study of births to enlisted U.S. Navy mothers between 1987 and 1989 
reported no significant difference in incidence of HDP across jobs regardless of the position’s 
ranked risk, but deployment status was not assessed.40  It is unknown if this trend is consistent 
across military branches or with current wartime conditions experienced by active-duty women.  
In a recent exploratory analysis of post-9/11/2001 veterans who used Veteran’s Health 
Administration (VHA) maternity benefits, Katon et al.19 found that compared to general 
population births in the Nationwide Inpatient Sample, veterans were more likely to develop HDP 
(SIR=1.32, 95% CI: 1.15-1.51).       
 
Araneta et al.41 investigated the risk of miscarriage, ectopic pregnancy, and stillbirth among 
3,825 women who were active-duty in the U.S. military in 1991.  They compared women who 
conceived during deployment or after returning home from the Gulf War to women who never 
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deployed.  Their only statistically significant findings showed that women conceiving post-
deployment were more likely to have a miscarriage (OR=2.90, 95% CI: 1.86-4.53) or ectopic 
pregnancy (OR=7.35, 95% CI: 2.97-18.2) than non-deployers.  Individual-level deployment data 
was not available and self-reported dates of deployment were obtained through survey in 1998, 
potentially leading to misclassification of the conception period.  Two other studies by the same 
author investigated the risk of birth defects among active-duty Gulf War veterans in several U.S. 
states.  Overall, they only reported one significant finding among female veterans for 
hypospadias (OR=6.3, 95% CI: 1.5-26.3), but used non-deployed veterans as the comparison 
group and did not adjust for multiple comparisons.42,43  In a study examining births to military 
mothers deployed during the first trimester post-9/11/2001, Ryan et al.44 did not find any 
statistically significant association between deployment and adverse birth outcomes, but they 
did report that women in the Navy (OR=1.32, 95% CI: 1.10-1.58) and Reserves (OR=1.71, 95% 
CI: 1.23-2.37) were at increased risk of having infants with birth defects compared to mothers in 
other branches.  Four additional studies have explored the risk of birth defects among women 
deployed in the Gulf War or post-9/11 OEF/OIF, and none reported a significant association.45-48  
However, two limited exposure to burn pits only, which does not fully define the full range of 
stressors someone faces in theater.  Additional analytical epidemiologic studies are needed to 
clarify the risks associated with deployment overall, and especially in the etiology of HDP.          
 
Deployment Characteristics and Perinatal Health 
While stressful experiences during deployment necessitate investigation, so do certain 
deployment characteristics hypothesized to impact health.  Dwell time is defined as the interval 
military personnel spend at their home assignment between the end of one deployment and the 
beginning of the next.  For example, the Army’s goal is to have service personnel spend twice 
as much time at home than their deployment lasted, for a dwell time ratio between deployment 
and home time of 1:2.  This means that an individual who deployed for one year should spend 
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two years at home before deploying again.49  Although some policy exists regarding suggested 
dwell times, the epidemiologic literature is incomplete and contradictory on what is considered a 
healthy dwell time.50  While it seems intuitive that longer dwell times are preferred for optimal 
health, some have purported that military personnel with longer breaks between deployments 
have more time to adjust to their normal lives and can experience increased stress transitioning 
back to deployed status compared to individuals with shorter breaks.   
 
In an analysis of 1.3 million U.S. military personnel deployed between October 1, 2001 and 
December, 31, 2010, the percent of men and women diagnosed with PTSD increased as dwell 
times increased compared to breaks of less than six months; however, the trend was not linear.  
For individuals completing their second deployment, the riskiest dwell time was 12-18 months 
(RR=1.81), with a slightly lower risk for 18 or more months (RR=1.75) compared to <6 months.  
The trend held for each deployment through the fifth.  The authors did not examine deployment 
to dwell time ratios.51  Macgregor et al. conducted two analyses of U.S. Marines who deployed 
between January 2003 and December 2007 (n=65,704),52 and between January 2005 and 
December 2008 (n=3,512).53  In the larger study, the authors reported that individuals with the 
longest dwell time relative to deployment were protected against provider-diagnosed PTSD, and 
the result was statistically significant (dwell-to-deployment ratio 2:1 vs. <1:1, OR=0.47, 95% CI: 
0.32-0.70).  They reported similar results in the smaller study, but they did not reach statistical 
significance.  A July 2012 U.S. Military Medical Surveillance Monthly Report of post-deployment 
women’s health reported no association between dwell times and any medical complaint; 
however, no data was shown.  They further showed that PTSD was associated with 
deployments lasting more than nine months compared to shorter ones ending by month four 
(OR=1.73, 95% CI: 1.50-2.00 for 9-12 months duration and OR=2.24, 95% CI: 1.95-2.57 for >12 
months duration).54  Bleier et al. reported similar findings among the Australian military, with 
individuals deployed 8-10 months during the previous three years at greatest risk of PTSD 
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(OR=1.6, 95% CI: 1.1-2.2) or any self-reported condition (OR=1.3, 95% CI: 1.0-1.8).  They also 
found that deploying once (OR=1.4, 95% CI: 1.1-1.9) or at least twice (OR=2.1, 95% CI: 1.5-2.8) 
resulted in greater risk of screening positive for PTSD or any self-reported health condition.  
However, this study suffered from severe limitations with a response rate of approximately 45%, 
and deployment data unavailable for >50% of respondents.55 No studies examining the impact 
of dwell times and/or deployment duration on perinatal health were located, leaving an important 
gap in our current understanding of military reproductive health.   
 
Post-Traumatic Stress Disorder (PTSD)  
Most individuals demonstrate resiliency to acute stressors and return to a normal state after 
processing the traumatic event; however, some individuals exposed to particularly traumatic 
events progress to develop PTSD.  This disorder is characterized by four major symptom 
criteria that last one month or more: 1) Intrusion; 2) Avoidance; 3) Negative Cognition/Mood; 
and, 4) Hyperarousal.  Intrusion symptoms can include persistent negative memories, 
nightmares or repeated negative dreams, flashbacks, and upset after exposure to stimuli 
representative of or directly related to the event.   Avoidance is characterized by withdrawal 
from people or situations that might trigger memories, even if they are activities the individual 
once enjoyed.  On-going negative emotions related to the event, including self-blame, distrust, 
and ability only to feel negative emotions are indicative of the Negative Cognition/Mood criteria.  
Hyperarousal behaviors tend to manifest as excitability, the inability to sleep or concentrate, and 
aggressive outbursts.  Figure 1 illustrates the criteria groups.   
 
Symptoms typically appear within three months of the traumatic event, and about 50% of cases 
recover three months after onset.  However, chronic PTSD can develop with symptoms 
reappearing multiple times across the lifespan in response to reminders of the traumatic event 
or other intense life stressors.  Not all stressors are serious enough to cause this disorder.56  
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Experiencing or witnessing potentially life-threatening events such as sexual assault, natural 
disasters, motor vehicle accidents, violent death, or combat increases the risk of subsequent 
 
 
Figure 1.  DSM-V Criteria and Symptoms for PTSD. 
 
PTSD.57  The scenarios encountered by the military population are all included as part of the 
diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5), and being a perpetrator, witnessing atrocities, and killing enemies are specifically 
mentioned as risk factors for military personnel.56   
 
The lifetime prevalence of PTSD in the general population is approximately 8% based on results 
from the U.S. National Comorbidity Survey, but women reported PTSD twice as often as men 
(10.4% vs. 5.0%).58  The prevalence of PTSD among service personnel from OEF and OIF is 
slightly higher than the general population at 14%.58   Overall, exposure to life-threatening 
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events while deployed is most likely to lead to PTSD, while sexual assault, being threatened 
with a weapon,59 and working in the health care field51 results in the most cases among women.      
 
Only 11 epidemiologic studies exploring the impact of PTSD on adverse birth outcomes were 
located; however, 10 were among the general population and none included HDP.  The most 
common conditions studied were PTB, LBW, intrauterine growth restriction (IUGR), and birth 
defects.  Overall, six studies reported a statistically significant association between PTSD and 
certain adverse birth outcomes (head circumference, PTB, LBW, ectopic pregnancy, 
miscarriage and hyperemesis).16,60-64  Small sample size with few PTSD cases in the non-
significant studies substantially reduced their power, in addition to methodologic differences that 
limit the validity and comparability of their findings.65-69  There was also inconsistent timing of 
exposure across the studies ranging from pre-conception to any trimester of pregnancy.  It is 
important to understand how the timing of exposure impacts birth outcomes, and we lack this 
information with the state of the current literature.  Some studies may even suffer from reverse 
causality.  All studies intended to capture pre-birth PTSD as an exposure leading to an adverse 
birth outcome; however, a few conducted PTSD interviews related to the event after birth.  If a 
mother experienced a particularly difficult pregnancy related to HDP, her PTSD symptoms may 
have been related to the birth instead of the exposure despite being directed to frame her 
symptoms around the traumatic pre-birth event.    
 
For example, three studies conducted in New York City following the World Trade Center 
attacks on 9/11/2001,16,60,65 and one in Louisiana following Hurricane Katrina68 all potentially 
failed to establish temporality of PTSD among some participants.  All included women who were 
pregnant at the time of the disaster, but assessed presence of PTSD at the time of interview 
months to years later.  Berkowitz et al.65 did not specify when interviews occurred relative to 
September 11, but Engel et al.60 indicated exposure ascertainment took place on average 6.5 
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months after the attack and that 57% of the cohort was interviewed after giving birth.  Similarly, 
Lipkind et al.16 assessed PTSD up to 30 days prior to interview, but they were administered up 
to three years post-9/11/2001.  It is possible that the detected maternal PTSD resulted from 
birth complications or a post-birth traumatic event and was not related to 9/11/2001.  Each study 
used the same PTSD checklist to measure exposure, but applied different cut-points to the 
score to dichotomize their variable.  The Lipkind study relied on the lowest cut-point (score >44) 
and was the only study to find a statistically significant association between PTSD and both PTB 
(OR=2.49, 95% CI: 1.05-5.84) and LBW (OR=2.49, 95% CI: 1.02-6.08), but this study also 
contained the largest sample size of the three studies (n=599).  The number of PTSD cases 
might have been larger in these studies if exposure ascertainment occurred more proximal to 
the disaster since 50% of cases resolve within three months of onset.        
        
The remaining six general population studies were not focused on a particular traumatizing 
event, thus they included only the background rate of PTSD.  Participants comprised women at 
varying trimesters of pregnancy seeking OB care from physicians in Hawaii,66 New England,67,69 
or Michigan,61-63 and two studies limited their population to Healthy Start67 or Medicaid 
recipients.61  Varying instruments were utilized to categorize PTSD, which likely impacted the 
number of PTSD cases and comparability of exposure across studies.  In a cross-sectional 
analysis of Medicaid women, Seng et al.61 used the strictest definition of PTSD (ICD-9-CM 
diagnosis code 309.81) and found a statistically significant increased risk of PTB (OR=1.4, 95% 
CI: 1.1-1.9) in addition to other adverse outcomes; however, it is unknown if PTSD resulted from 
pregnancy and birth complications.  Using the Life Stressor Checklist and National Women’s 
Study PTSD Module among a general population of pregnant women, Seng et al.63 later 
reported that PTSD did not increase the risk of PTB (p=0.202) but current PTSD was associated 
with decreasing birth weight (p=0.001).  In the largest study to date among the general 
population (n=2,654 women), PTSD was assessed using the Modified PTSD Symptom Scale 
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and was not associated with PTB (OR=1.22, 95% CI: 0.57-2.61) but taking an SSRI 
antidepressant was (OR=1.55, 95% CI: 1.02-2.36).69     
 
In the only study among a military population, Shaw et al.64 investigated the risk of spontaneous 
PTB after PTSD diagnosis among 16,477 deliveries to women utilizing VHA maternity benefits 
from 2000 to 2012.  Each woman was screened for PTSD prior to birth, and PTSD was 
determined using ICD-9-CM code 309.81.  After controlling for demographics, military sexual 
trauma, recent deployment, and certain health conditions, they reported that women diagnosed 
with PTSD within the year prior to birth were 1.35 times more likely to experience PTB 
compared to women with no PTSD (95% CI: 1.14.-1.61).  They reported no almost association 
for PTSD diagnosed before this time period.  While this is a vital initial study among the military 
population, it excluded a large proportion of potentially effected women.  Only about one third of 
eligible female veterans take advantage of VHA health benefits.70  It is possible that women with 
PTSD sought VHA benefits more frequently than those without the condition, especially if they 
were unable to secure civilian employment with health insurance.  This could introduce bias in 
the direction of the results observed in the current study.      
 
PTSD has been linked to cardiovascular disease and hypertension among individuals with 
trauma or military history.7,8,71  In a cross-sectional study of OEF/OIF veterans, those with PTSD 
or other mental health conditions were more likely to have hypertension (OR=2.88, 95% CI: 
2.79-2.97), and also had higher resting heart rates than healthy veterans.72  Granado et al.73 
also reported that individuals deployed to OEF/OIF with combat experience were 33% more 
likely to develop incident hypertension compared to deployed personnel with no combat 
experience (95% CI: 1.07-1.65).  The underlying mechanism is hypothesized to be 
dysregulation of the HPA axis and neurochemical processes.  Individuals with PTSD have 
overactive norepinephrine (NE), which has roles in regulating arousal and blood flow to organs 
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in response to a stressor.  When NE is not downregulated and this part of the nervous system 
remains “on”, hyperarousal PTSD symptoms result, including sustained increased heart rate 
and increased blood pressure.6     
 
The DOD currently administers two health assessments to members of the U.S. Armed Forces 
at the conclusion of each deployment in order to screen for medical and mental health 
concerns.  The Health Assessment Program was initiated in 2003 to detect mental health issues 
among troops deployed post-9/11/2001 to Afghanistan and Iraq during OEF and OIF.  Only 
deployed individuals sent outside the U.S. for >30 days to support a military operation located in 
an area without a medical facility capable of providing long-term care complete health 
assessment forms.  Form 2796 Post-Deployment Health Assessment (PDHA) is given within 30 
days of deployment end and is often completed during in-theater out-processing before the 
individual returns home.  Form 2900 Post-Deployment Health Reassessment (PDHRA) is then 
completed 90-180 days later.  A health care professional reviews all forms and suggests 
referrals for more rigorous assessment when indicated by the responses. The PDHA has been 
administered since the program began in 2003, while the PDHRA was instituted in 2005.  Both 
forms were expanded in 2008 to include additional questions on traumatic brain injury and 
alcohol consumption.74       
 
There are specific questions on both the PDHA and PDHRA that attempt to screen for mental 
health disturbance, including PTSD.  Questions ask if the individual encountered dead bodies, 
discharged their weapon, felt in danger of being killed, has been recently depressed, 
disinterested, on guard, avoiding situations, detached, or having nightmares/unwanted thoughts.  
The last four questions are specifically designed to screen for PTSD, with each question 
representative of a symptom category.  Table 1 illustrates the text of each question in relation to 
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its symptom category.  Two or more positive responses indicates referral for more rigorous 
PTSD assessment.75 
 
A few validation studies/exploratory analyses exist pertaining to certain PTSD-related questions 
on the PDHA and/or PDHRA.76-80  The largest study utilized records from 58,242 active-duty 
 
Table 1. PTSD-Specific Question on the PDHA/PDHRA according to DSM Criteria. 
 
Have you ever had any experience that was so frightening, horrible, or upsetting that, IN THE 
PAST MONTH, you… (Yes/No Responses) 
 
Intrusion  
(Re-Experiencing) 
Avoidance and Negative Cognition/Mood Hyper-Arousal 
1. Have had 
nightmares about 
it or thought about 
it when you did 
not want to? 
2. Tried hard not to 
think about it or 
went out of your 
way to avoid 
situations that 
remind you of it? 
3. Felt numb or 
detached from 
others, activities, 
or your 
surroundings? 
4. Were constantly 
on guard, 
watchful, or easily 
startled? 
 
 
 
U.S. Air Force personnel between January 1, 2008 and December 31, 2008.76  The authors 
considered individuals with an ICD-9-CM code for PTSD, and assessed how well positive 
responses on PTSD screening questions predicted a true PTSD diagnosis.  Compared to 
Airmen with negative PTSD screenings, individuals who screened positive for PTSD on the 
PDHRA (according to the criteria discussed above) were more likely to have medically 
confirmed PTSD also.  The sensitivity for positive PDHRAs was 0.65 and specificity was 0.74.  
The authors further assessed the individual utility of multiple PDHRA questions in predicting 
PTSD through structural equation modeling, and reported that conflict in important relationships, 
nightmares, and avoidance were most associated with a confirmed PTSD diagnosis.  However, 
currently being on guard or being shot, involved in a motor vehicle accident, or exposure to a 
blast all during deployment were also predictive of true PTSD to a lesser but statistically 
significant degree.  Three of the remaining studies were conducted by Bliese et al. among small 
samples (n<1,600) of the U.S. Army.78-80 They compared the four PDHA questions to clinician 
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diagnoses, and reported conflicting results.  In one study, the best sensitivity and specificity was 
associated with two (sensitivity=0.85, specificity=0.71) and three positive responses 
(sensitivity=0.76, specificity=0.88),78 while one (sensitivity=0.86, specificity=0.73) and two 
(sensitivity=0.73, specificity=0.88) responses maximized the measures in another study.79,80 
 
Since PTSD and deployment have been shown to increase the risk of cardiovascular disease 
among veterans, and linked to certain adverse birth outcomes, it is imperative to quantify the 
risk of HDP among active-duty women who are deployed, diagnosed with PTSD or exhibit 
hallmark symptoms of the disorder.   
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CHAPTER 3 
Methods 
 
 
We conducted a retrospective cohort study using a U.S. DOD database comprised of all active-
duty women who gave birth using Tricare from January 1, 2004 to December 31, 2008.  Tricare 
health insurance was available to all current and retired military personnel and their families, 
and most active-duty personnel subscribed.81   The database included: 1) maternal and infant 
birth hospitalization records, 2) maternal inpatient and outpatient mental health visits for the 
study period, and 3) deployment records that included post-deployment health assessments 
and re-assessments completed during the study period.  Each data file contained a unique 
identifier created randomly by the DOD.  Names and social security numbers were removed by 
DOD, and maternal date of birth was masked.  The only patient demographic identifiers that 
remained were mother’s age and month/year of delivery.  All dates for events such as 
diagnoses and deployments were calculated in days from the mother’s first birth during the 
study period to the event.  For example, a deployment that ended 12 months prior to birth had a 
recorded end date of -365.  All data were collected prior to the October 15, 2015 implementation 
of ICD-10-CM; therefore, all medical diagnoses and procedures were coded using ICD-9-CM.82      
 
Overview of Study Population 
Our study population consisted of active-duty military women who delivered their first, live-born 
singleton infant between January 1, 2004 and December 31, 2008 as identified in the infant birth 
database using the ICD-9-CM codes listed in Appendix 1, Table 1.  There were 69,575 total 
births during the study period.  After excluding multiple/unknown plurality births (n=3,808), 
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secondary or higher births (n=29,048), and births outside our study period (n=13), there were 
36,706 births that met our eligibility criteria.  We merged this dataset with the mother’s inpatient 
hospitalization file using the unique identifier and year of birth to create a master study 
population file.       
 
Tricare assigned each dependent on a woman’s health care plan a specific family member 
code.  Any children on a mother’s plan were counted in order of age, so that the oldest child 
was classified as child #1, the next child as #2, and so on.  If a mother joined Tricare with 
existing children and then gave birth, that first child born on Tricare would be assigned the 
appropriate family member code based on its birth order.  Thus, we first restricted to first births 
within the study period, and then to births with a family member code of one.  There is a chance 
we misclassified some birth orders based on this methodology.  If a mother adopted children 
prior to giving birth to her first biological child on Tricare, that infant would not receive a family 
member code of one and would be ineligible for our study despite being the mother’s first birth.  
Also, the possibility of error exists if a woman’s partner was also on Tricare.  For example, if 
previous biological children were dependents on the father’s Tricare and the mother gave birth 
for the first time on Tricare during our study period, then that infant would be coded as the 
mother’s first child and included in our study population.       
 
Women who became pregnant while on active-duty but left the service prior to birth were not 
included in the data.  However, if the pregnancy was known at the time of discharge, the woman 
was offered Tricare coverage for her healthcare through labor and delivery.  Lastly, any active-
duty woman giving birth off Tricare was also missed, but few active-duty women utilize 
alternative insurance coverage.81       
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Outcome Definition 
We ascertained the presence of HDP conditions using ICD-9-CM diagnosis codes from the 
mothers’ records in the merged birth file previously discussed.  Table 2 in Appendix 1 denotes 
the specific codes used to define the outcome.  According to a validation study conducted in 
Australia that compared hospital coding using ICD-10-CM codes to medical record review, 
Roberts et al. reported that the sensitivity of hospital discharge coding for all HDPs together was 
68.2% and the specificity was 99.6%.  Sensitivity was lowest for chronic hypertension (44.4%), 
but increased for gestational hypertension (47.8%) and preeclampsia (71.0%) while specificity 
remained similar.  Interestingly, sensitivity and specificity were very high for first time mothers 
when examining all HDPs together (sensitivity=80.1%, specificity=100%).83  Some 
misclassification may have occurred by using diagnosis codes in our study; however, it is 
reasonable to assume that it was likely non-differential if it occurred.   
 
Any woman who had at least one type of coded HDP in any of her birth hospitalization(s) was 
considered to have our study-defined outcome of interest.  We created an overall HDP variable, 
and also classified the subtypes as shown in Appendix 2, Table 1.  We used a hierarchical 
approach for women with multiple diagnoses, assigning them to the most severe category.  For 
example, a mother diagnosed with both gestational hypertension and preeclampsia was 
assigned to the preeclampsia group.  Women were only classified in the unspecified group if 
they lacked a more specific HDP code.  Very few women developed eclampsia, and no cases 
received this code without first being diagnosed with preeclampsia.  Therefore, we did not 
examine eclampsia cases as a separate group.  Women with pre-existing chronic hypertension 
were treated as chronic hypertension complicating pregnancy cases (n=8) since it is customary 
in obstetric care to treat these women as cases in this category (H. Rawji, MD, personal 
communication, January 30, 2017).  
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Analysis Dataset Merge 
The master deployment database contained deployment records for all mothers beginning 
January 1, 2001, which included variables related to deployment beginning and end dates, 
occupation, deployment location, and service branch.  We combined this dataset with our birth 
dataset described above to keep deployment records for mothers meeting our eligibility criteria.  
We included only deployments that were completed before birth, and that lasted ≥30 days.  
Mothers in the deployment database were coded as deployed and mothers in the birth dataset 
who did not appear in the master deployment file were categorized as non-deployed.  We 
discovered that 103 deployment records were missing deployment end dates.  We matched 
these records to the mother’s PDHA and imputed the date if the start dates were within 16 days 
of each other.  We were able to impute 44 records, and excluded the remaining 59.  
Additionally, if two records for the same mother had a start or end date within five days of each 
other the earlier record was kept (23 records excluded).  The final merged deployment file 
contained 36,675 mothers.     
 
We next added the military demographic, PDHA and PDHRA files to the deployment file.  We 
found that 491 mothers who completed a PDHA and 55 mothers who completed a PDHRA 
without a PDHA were missing from the master deployment file.  We flagged those women and 
updated the deployment variable to reflect their deployment.  We also identified and flagged 21 
women who deployed >1 with overlapping deployment start and end dates, 1,784 women with 
missing military entry dates, and 86 women who either spent >100% of the study period 
deployed or whose military entry date was later than her first deployment.  These represented 
DOD data entry errors.      
 
There were 387 PDHAs missing deployment start dates, 854 missing end dates, and 270 
missing both.  We imputed 46 start dates and 359 end dates from the master deployment dates, 
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and excluded the remaining records.  We also excluded records if the start or end dates were 
within five days of each other (n=2,055 records).  After all exclusions, 8,801 deployed mothers 
had at least one PDHA, for a total of 10,201 completed PDHAs.  Missing was quantified across 
the variables needed to define our PTSD exposure, and a total of 1,285 records were flagged.  
There were 3,564 PDHRAs meeting our eligibility criteria.  We matched these to the PDHA 
records by deployment start and end dates to assess agreement between PTSD screenings.  
Some PDHRA records also had some missing on the PTSD-related variables (n=99), and these 
records were flagged.  A total of 2,419 PDHRAs were matched to a PDHA.  There were 722 
mothers who completed a PDHA that did not match to a PDHRA.  Finally, we combined the 
maternal inpatient and outpatient mental health visit records to identify eligible women who had 
any physician-diagnosed PTSD before birth and added the earliest diagnosis to the analysis 
dataset.  Mothers in the dataset with no confirmed PTSD were coded as non-cases. 
 
Potential Confounders and Covariates  
Several important covariates were explored in all our aims.  Variables available for the entire 
cohort: maternal age at the time of birth (18 to 24 years, 25 to 29, 30 to 24, 35+), race (white, 
black, Hispanic, other), marital status at birth (married, single/never married, other), pay grade 
(enlisted or officer), and maternal medical conditions including the presence of pre-gestational 
diabetes (identified using ICD-9-CM diagnosis codes shown in Appendix 1, Table 3 in the 
maternal birth hospitalization record).  Certain variables were only present for mothers who 
deployed: military branch (Army, Air Force, Navy), deployment location (Iraq/Afghanistan, 
Southwest Asia, Kosovo), and occupation (combat, healthcare, other).  Women serving in the 
Coast Guard and Marines were included with the Navy due to small sample size in these two 
branches.  The Marines are a subset of the Navy, and while the Coast Guard operates under 
the Department of Homeland Security, they deploy with the Navy when activated.  The military 
is also subject to immunizations at boot camp, prior to deployment, and at recommended 
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intervals for boosters.  While our data did not capture specific vaccines administered, we 
explored the use of deployment location as a proxy to create a vaccine variable indicating 
deployment-specific vaccines in excess of baseline in order to adjust for vaccination history.  
Since 99% of our deployed mothers were deployed to OEF/OIF, we did not use this variable in 
our models.  Variables that were available for deployed mothers only were not added to any 
regression models that included non-deployed mothers.  All variable definitions are presented in 
Appendix 2, Table 5. 
 
Although obesity and smoking modify the risk of HDP,22 this information was not collected and 
was unavailable for analysis.  However, since our study population was comprised of active-
duty military who were required to meet fitness standards as a condition of service, chronic 
medical conditions, and overweight/obesity likely did not impact a large number of participants.  
According to the most recent DOD Health Behaviors Survey conducted in 2011,84 about 60% of 
active-duty women were at a healthy weight as measured by body mass index (BMI), and 83% 
were former or non-smokers.  Among women that did currently smoke, 12% reported moderate 
to heavy use.  Younger women and those who were enlisted were more likely to smoke than 
older women and officers.  Smoking prevalence also differed according to service branch, with 
the Marines most likely to smoke (23%) and Air Force least likely (15%).  We were able to 
somewhat control for these health behaviors by including age and pay grade in statistical 
models for the entire cohort, and by including branch in models including deployed women only. 
 
Specific Aim 1 Deployment Exposures 
Deployment Definition.  Pre-birth deployment in the post-9/11/2001 era (beginning January 1, 
2001 or after) was the main exposure of interest. Deployments are distinguished from other 
types of military travel.  Individuals are considered deployed when assigned to a location that 
lacks a permanent U.S. military medical treatment facility outside the U.S. for >30 days.85  For 
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example, a service person given temporary duty at a base in Japan with a U.S. military clinic is 
not considered deployed despite the amount of travel involved or length of stay; however, 
assignment to Afghanistan for >30 days does constitute a deployment since there is no 
permanent hospital or medical clinic there.  All specialty terms and main variable definitions are 
presented in Appendix 2, Table 2. 
 
Previous Research. This data was obtained and analyzed previously under a 2008 grant by 
Kathleen O’Rourke, PhD, Faculty Advisor (USF IRB# 106906).  One unpublished research 
paper exists examining the effect of deployment on the incidence of LBW and PTB.  Four 
categories of deployment before birth were used: <12 months, breaks between the most recent 
two deployments of <6 months, deployments lasting >15 months, and cumulative deployment 
≥12 months prior to birth.  The only statistically significant finding showed an increased risk of 
both LBW (OR=1.27, 95% CI: 1.10-1.46) and PTB (OR=1.31, 95% CI: 1.11-1.53) among 
mothers whose last deployment ended <12 months prior to birth compared to those with a 
longer deployment interval after adjusting for maternal age, race, marital status, educational 
attainment, military branch, pay grade, and infant gender.  These findings informed the 
hypothesis in the current aim. 
 
Deployment Measures.  The following describes the specific measures of deployment we 
analyzed.   
1. Deployed vs. Non-deployed: Any woman who had at least one deployment during our 
study period that ended prior to birth was considered deployed.  We compared this 
group to women who gave birth during the same time period (January 1, 2004 to 
December 31, 2008) but who had no deployment record prior to birth.   
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Women we flagged who were missing from the DOD master deployment file but completed a 
PDHA or a PDHRA were not included in the following analyses since complete deployment 
history was not available. 
   
2. Deployment ending <12 months or ≥12 months before birth vs. Non-deployed: Women 
whose most recent deployment ended <365 days before birth or ≥365 days before birth 
were compared to non-deployed women as the reference group.  We also explored the 
association with the flagged women as an additional “missing” category.       
3. Cumulative Weeks of Deployment (continuous). We quantified the total weeks each 
woman spent deployed prior to birth to explore dose-response trends restricted to 
deployed women only.       
 
Statistical Modeling. All statistical analyses were performed using SAS version 9.4 (Cary, NC).  
We first explored descriptive statistics for our main deployment exposures and important 
covariates in association with our overall HDP outcome.  Chi-square tests of homogeneity 
(Fisher’s Exact test when any cell was ≤5) were performed for all categorical variables and t-
tests for continuous variables using a 5% level of significance, and missing was quantified for 
each variable.  We built one logistic regression model for each of our three main deployment 
exposures and HDP.  Based on public health and biological significance, we decided to leave all 
covariates in the models whether or not they confounded the observed association, and records 
with missing values were excluded prior to entering a variable into the model. The cumulative 
weeks of deployment model only included deployed women so we could examine the effect of 
service branch and occupation.  We reported odds-ratios (ORs) and 95% confidence intervals 
(CIs).  Mothers with missing data on any variables included in a specific model were excluded 
from that analysis.   
26 
 
 
Sub-Analysis: Stratification by Race.  Racial disparities in general population epidemiologic 
studies on various health outcomes are well documented,86-88 and certain research indicates 
that black mothers experience greater risk of HDP compared to whites.89,90  Our study 
population provided a unique opportunity to investigate racial disparity in HDP incidence since 
socioeconomic status was more standardized than in the general population.  For example, all 
of our mothers possessed the same access to health care, were required to maintain certain 
physical fitness standards, were subjected to the same medical screenings, and were paid 
equally by rank.  We therefore re-ran the analyses described above stratified by race (white, 
black, Hispanic, other) without race included in the model.  Women with pre-gestational 
diabetes were excluded from these analyses due to small numbers with the additional 
stratifications. 
 
Sub-Analysis: HDP Types.  To explore the association between our deployment exposures and 
specific HDPs, we repeated the main logistic regression described above for the three 
deployment exposures using each of the four HDP types as discrete outcomes.  Only women 
without any HDP were included as the comparison group.       
 
Sub-Analysis: Timing of Conception.  We approximated the timing of conception for everyone in 
the cohort based on gestational age, prematurity, and respiratory distress syndrome (RDS) ICD-
9-CM codes in the infant’s hospitalization record (Appendix 1, Table 4).  Approximately 88% of 
the population was missing a gestational age code.  We explored whether or not any of these 
records had an indication of prematurity or RDS, a condition highly correlated with prematurity.  
For the remaining records still missing a code, we assumed that they were somewhere between 
≥37 and 40 weeks gestation since they lacked a specific code available for other gestational 
lengths.  Records with unspecified or non-specific gestational ages were excluded (i.e. <24 
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weeks gestation, premature with no gestational age), and infants with gestational age >42 
weeks were included in the 40-42 weeks category.  We calculated the approximate conception 
date in days before birth by multiplying the midpoint of the gestational age range by seven.  We 
then determined whether or not the pregnancy was conceived during the most recent pre-birth 
deployment and categorized women as conceiving before, during, or after deployment as 
compared to non-deployed women.  We examined this as a fourth deployment exposure using 
the entire cohort.        
 
Sub-Analysis: Military Entry Timing. We also examined whether or not pre-2001 entry to the 
military confounded the observed associations for the three deployment measures.  In these 
analyses, women flagged with military entry date errors were excluded (n=1,842). 
 
Specific Aim 2 Deployment Exposures 
Deployment Measures. We explored cut-points for categorization of the following continuous 
deployment characteristics among deployed women only:  
1. Cumulative weeks of deployment: defined as the cumulative weeks of pre-birth 
deployment in the study period. 
2. Percent of time in study period spent deployed: calculated as the total number of days 
spent deployed prior to birth divided by the total number of days spent in the military 
during the study period prior to birth.  Women missing a military entry date and those 
with entry date errors were excluded. 
3. Dwell time: calculated as the cumulative number of weeks between the ending and 
beginning of the two most recent pre-birth deployments.  Only women with >1 
deployment were included when examining dwell time measures.   
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4. Dwell time ratio: calculated as the duration in days of the second most recent pre-birth 
deployment divided by the dwell time in days between it and the most recent pre-birth 
deployment.  
 
Mothers flagged as completing a PDHA or PDHRA but not included in the original master 
deployment file or with overlapping dwell times were not included in these analyses.  These 
terms are also found in Appendix 2, Table 3.   
 
Statistical Methods. We used non-parametric classification tree analysis (CART) using PROC 
HPSPLIT in SAS to identify meaningful cut-points for our four deployment measures related to 
our HDP outcome.  CART uses recursive partitioning that begins by aggregating the entire 
sample into one group, and then splits the data into successive sub-groups by determining 
which cut-points of a particular exposure variable (or variables) result in the most homogenous 
groups according to outcome.  Output is illustrated as a tree.  The top of the tree is represented 
by the root node that contains the entire data set.  The tree is split into branches leading to child 
nodes.  When a particular branch cannot be split any further, it ends in a terminal node.  The 
cut-points and proportion of the outcome in each node are shown on the output tree.  Trees can 
grow quite large and be difficult to interpret practically without specifying a pruning method.  To 
select the most parsimonious tree, the data is fitted on a subset of the sample (training) and 
then fit to the remaining data (validation).  We used the cost-complexity pruning method, which 
outputs the least complex tree that has the lowest error rate among the validation sample.  We 
specified that 80% of our sample be used for training and 20% for validation.  Further, we used 
gini as our splitting criteria to maximize homogeneity in each child node.91-93  In order to make 
interpretation meaningful in public health practice, we limited our trees to eight branches for 
each of the four exposure variables in this aim.     
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First, we produced one tree for each of the four deployment measures alone versus HDP.  
Then, we examined the added importance of age, race, marital status, pay grade, branch, and 
occupation by producing one tree for each variable plus the deployment measure versus HDP.  
A full tree with all variables versus HDP was also examined for each of the four deployment 
measures.  Relative importance was judged for the deployment measures alone and then by the 
additional covariates.  Once cut-points were determined for the most important measures, we 
categorized them and fit logistic regression models as previously described to report ORs and 
95% CIs for the association with HDP.  
 
Specific Aim 3 PTSD Exposures 
Exposure Definition. We identified women with PTSD from the entire cohort and then among 
women who completed a PDHA.  All the main terms and variable definitions used in this Aim are 
located in Appendix 2, Table 4.   
 
1. Confirmed Cases. Women diagnosed with PTSD identified from inpatient and outpatient 
records using ICD-9-CM code 309.81 prior to birth were considered a confirmed case.  
Also, women with a new PTSD diagnosis in the birth hospitalization record were also 
considered confirmed cases.  
2. Probable Cases. Women who fit the possible case definition and who endorsed at least 
one other “high-risk” or depression screening question as shown in Appendix 2, Table 4 
were considered a probable case. 
3. Possible Cases. Women endorsing ≥3 of the PTSD screening questions (Appendix 2, 
Table 4) on a PDHA prior to birth were considered a possible case.   
4. None. Women with negative screenings across all pre-birth PDHAs and who lacked a 
medical diagnosis were considered unexposed and comprised our comparison group.  
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We selected the possible cut point based on how PTSD diagnosis is made using the PTSD 
Checklist – Military Version (PCL-M).  The PCL-M is a 17-item questionnaire aligning with DSM-
IV diagnosis criteria, and the number and clustering of statements that are endorsed are used to 
screen for PTSD.  Moderate PTSD is diagnosed based on ≥1 intrusion, ≥3 detached or 
avoidance, and ≥2 hyperarousal endorsements.  The four PTSD screening questions on the 
PDHA represent these symptom categories, and by requiring endorsement of ≥3 we minimized 
the false-positive rate of PTSD in our sample.94             
 
In a large meta-analysis, Rytwinski et al. examined the correlation between clinical depression 
and PTSD using 57 civilian and military studies.95  They reported coexistence of the two 
conditions in 52% of PTSD cases, but when restricted to military studies, the prevalence 
increased to approximately 65%.  Similarly, the correlation between the two among PTSD 
women in a general population survey was about 50%, and women with PTSD were four times 
more likely to experience depression than women without PTSD (OR=4.07, 95% CI: 3.08-
5.29).96  There is likely considerable overlap between the conditions in our study population, 
making it probable that an individual meeting the possible case definition who also endorsed the 
depression question(s) did have PTSD.  Likewise, engaging in combat, being threatened by a 
weapon, or comparable traumas have been associated with development of PTSD and further 
strengthens our case definition.3,96  Rape and sexual assault are highly predictive of PTSD 
among women; and, unfortunately does occur among the military population.  We possess no 
data to account for its occurrence in our study population.96  In a 2014 DOD survey conducted 
by the RAND Corporation of the military workforce, just under 5% of active-duty women 
reported sexual assault in the preceding year.35  In an analysis using data from the Millennium 
Cohort Study, a prospective study of health among current military and veterans, LeardMann et 
al. reported that 10% of women participants had experienced unwanted sexual attention in the 
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three years since baseline.  Most attention was in the form of sexual harassment, but 8.9% of 
the unwanted attention was sexual assault.  When restricting to women who deployed during 
the study period, there was a high correlation between combat and sexual assault.  Specifically, 
women endorsing similar questions to our “high risk” assessment reported the most sexual 
harassment (19.9%) and sexual assault (4.0%) compared to women who did not experience 
combat or who did not deploy.97  The relationship is likely due to women in the highest combat 
zones being most at risk of sexual assault for unknown reasons, and they therefore are also 
commonly exposed to the situations described in the “high risk” questions.  Regardless, there is 
some overlap of unwanted sexual attention and endorsement of these items, further 
strengthening our probable case definition.                
 
A hierarchical approach was used to categorize women into the most stringent category they 
met.  For example, if a woman met both the probable and confirmed case-definitions, she was 
categorized as confirmed.  For women with multiple PDHAs, the earliest record where they met 
the most stringent case definition was kept, including women categorized as missing.  A woman 
was only captured as missing if none of her other PDHA records or medical records fit her into a 
higher category.        
 
Mini-Sensitivity Analysis. The possible case-definition using ≥3 endorsements on the PTSD 
screening portion of the PDHA limited the false-positive rate by employing strict parameters for 
defining a case.  However, we re-ran the analyses that included PTSD case-definition 
categories after an expansion of the possible definition to include women endorsing ≥2 
questions on the PTSD screening questions.  The probable category parameters remained the 
same.  
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Statistical Modeling. We first examined descriptive bivariate analyses between PTSD, the 
covariates/potential confounders discussed in Specific Aim 1 Methods, and our overall HDP 
outcome.  We compared frequencies using chi-square tests of homogeneity with a 5% level of 
significance and Fisher’s Exact test when any cell was ≤5.  Logistic regression was performed 
and the OR and 95% CI for the association between PTSD and HDP overall controlling for the 
important covariates were reported.  Women with missing values for any variables included in 
the models were excluded.  The specific models are described below.       
 
Analysis 1: Overall Cohort. We assessed the association between confirmed PTSD and overall 
HDP among deployed and non-deployed women, with women lacking any ICD-9-CM diagnosis 
serving as the reference group.  The analysis was repeated comparing women with any 
indication of PTSD (confirmed or screening) to women without any PTSD indication.      
 
Sub-Analysis: Effect Modification by Deployment. Using the entire analysis dataset, we explored 
the impact of effect modification between confirmed PTSD and deployment on HDP.  The 
analysis was repeated comparing women with any indication of PTSD (confirmed or screening) 
to women without any PTSD indication.  
 
Sub-Analysis: Stratification by Race.  As in Specific Aim 1, we conducted our any PTSD and 
HDP analysis stratified by race (white, black, Hispanic, other) without race included in the 
model.  Again, women with pre-gestational diabetes were excluded due to small sample size.  
        
Sub-Analysis: HDP Types.  We repeated the any PTSD analysis using the four sub-types of 
HDP as individual outcomes.  Only women without any HDP were included as the comparison 
group.  
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Analysis 2: PDHA Mothers. We assessed the association between PTSD and HDP among all 
women completing a PDHA using the case-definition described above.  We repeated the 
analysis using the relaxed ≥2 case-definition for PTSD among PDHA mothers.  For both, we 
also examined the association by adding the missing women into an additional variable 
category.  The following sub-analyses were also performed for both case-definitions. 
 
Sub-Analysis: Stratification by Race.  We also repeated the overall PDHA/HDP analyses 
stratified by race (white, black, Hispanic, other) without race included in the model.  Again, 
women with pre-gestational diabetes were excluded due to small sample size.         
 
Sub-Analysis: HDP Types.  We repeated the main logistic regression analyses using the four 
sub-types of HDP as individual outcomes.  Only women without any HDP were included as the 
comparison group. 
 
Sub-Analysis: Timing of Conception. We used the estimated conception dates calculated in Aim 
1 to quantify how long prior to conception PTSD was diagnosed or reported.  The date of 
earliest confirmed ICD-9-CM diagnosis or deployment end date for the earliest PDHA screening 
was used as the reference date.  We created “shorter” and “longer” categories by classifying 
women as first positive between conception and birth, <1 year before conception, or ≥1 year 
before conception vs. women without any positive PTSD indicator as the reference group.     
 
Sub-Analysis: Pre-Post Comparison: Among women who had matching PDHRA, we assessed 
the relationship between agreement categories and overall HDP to explore whether or not 
women with “chronic” PTSD screenings were at increased risk.  Women without any PTSD 
served as the comparison group.  
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Sub-Analysis: PDHRA Mothers Only.  We conducted the main analysis using our PTSD 
screening case-definition among only women who completed a PDHRA. We examined the 
association between PTSD and HDP using both the ≥3 and ≥2 case-definitions with the same 
reference group. 
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CHAPTER 4 
Results 
 
Overall Cohort   
Our study population included women giving birth to their first infant, and as expected, differed 
slightly from the overall female military population.  Table 2 illustrates the overall demographic 
characteristics of our population with a column for female military estimates.  Our mothers were 
younger (65.4% under 25), predominantly white (50.3%) or black (25.9%), and either married 
(65.1%) or single and never married at birth (32.1%).  By way of comparison, about 40% of 
women in the military in 2013 were under 26 years old,38 and in 2008, 53% were white, 31% 
black, and 13% Hispanic.  Also, fewer women in the military were married (46%).5,98  The 
majority of mothers were enlisted at the time of birth (89%) compared to 83% in the entire 
military, and just under 30% entered military service prior to 2001.98  Very few of our mothers 
had pre-gestational diabetes (<1%) or confirmed PTSD (1.6%), and about a third deployed 
during the study period (35%).  Just over 4,900 mothers (13.4%) experienced at least one HDP, 
with mothers over 35 years old experiencing a significantly higher HDP incidence than younger 
mothers (19.1% vs. 13.1-13.7%, p<0.0001) as shown in Table 3.  Black women were most likely 
to experience an HDP (15.7%), and Hispanic women were the least likely (9.9%, p<0.0001).  
We also observed a significantly higher incidence of HDP among enlisted women compared to 
officers (13.5% vs. 12.3%, p=0.03) and among women who had pre-gestational diabetes 
(30.0% vs. 13.4%, p=0.002).  No other significant differences were observed.   
 
The most common type of diagnosed HDP overall was preeclampsia (55% of HDP cases), 
followed by gestational hypertension (32.8%), chronic hypertension (9.5%), and unknown 
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hypertension (2.7%) as presented in Table 4.  A similar distribution was seen by race/ethnicity, 
but a larger proportion of Hispanic mothers had preeclampsia than the overall cohort (63.8%).  
Whites had a slightly lower proportion of preeclampsia compared to the overall cohort (51.3%), 
while blacks and other race mothers were closer to the overall percentage (57.9 and 56.8%, 
respectively).  We examined the frequencies of our main covariates and exposures by 
racial/ethnic category (data not shown).  The majority of mothers in each category were under 
30 years old, but Hispanic mothers were the youngest (93.0% under 30) and white mothers 
oldest (86.9% under 30).  Whites were also most likely to be married at birth (71.6%) and blacks 
least likely (51.3%).  Whites and mothers of other race had the highest proportion of officers 
(15% and 11.8%, respectively), with only about 5% of black and Hispanic mothers in the officer 
pay grade.          
 
Specific Aim 1 Deployment 
Descriptive Characteristics.  Descriptive statistics for the three main deployment exposures 
and covariates for deployed women only are presented in Tables 5 and 6.  Overall, 35.0% of 
mothers deployed and 98.8% of them were deployed in service of OEF/OIF (Table 5).  The 
majority of mothers were in the Army (37.8%) or Navy (39.2%).  Compared to the female 
military force overall (deployed and non-deployed), fewer women in our study held combat 
positions (10.6% vs. 15%).  In the general military, more women served in the Air Force than in 
our study (31% vs. 23%), the same proportion in the Army (37% vs. 38%), and fewer in the 
Navy (32% vs. 39%).5   However, since Coast Guard and Marines were combined with our Navy 
category, we expected the proportion of women in this group to be slightly higher.  As of 2009, 
about 50% of all active-duty women had been deployed to Iraq and/or Afghanistan compared to 
35% of our population.70 
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There was no significant difference in HDP incidence between deployed and non-deployed 
mothers (13.6% vs. 13.3%, p=0.47) as shown in Table 6, and no difference by timing of 
deployment end prior to birth.  Although slightly more mothers whose last deployment ended 
≥12 months before birth developed an HDP (14.0%) compared to deployments ending <12 
months before birth (13.0%) and the non-deployed (13.3%), the difference was insignificant 
(p=0.21).  Similarly, no significant difference was found for timing of deployment relative to 
conception, deployment location, or cumulative weeks of pre-birth deployment.  However, HDP 
incidence did differ by service branch and occupation.  Mothers in the Air Force experienced the 
highest incidence of HDP (15.4%) compared to the Army (13.5%) and Navy (12.6%, p<0.0001), 
and mothers in combat roles had a much lower incidence of HDP compared to mothers in 
healthcare occupations (11.5% vs. 15.5%, p=0.01).    
 
When stratifying by race in our cohort (data not shown), the most common branch for all races 
except blacks was the Navy, with blacks most likely to serve in the Army.  Women in the Air 
Force were more likely to develop an HDP across all races, but the observed differences were 
not statistically significant.  Similar to the overall cohort, whites, blacks, and Hispanic women in 
combat roles had slightly lower HDP rates, but the incidence was similar across all occupational 
roles for women identifying as other race.  HDP incidence was only higher for whites in a 
healthcare occupation compared to the other roles.  When examining differences across the 
deployment exposures, black women were the only racial/ethnic group to experience a 
statistically different HDP rate if deployed (16.8% vs, 15.0%, p=0.02), and if deployment ended 
≥12 months prior to birth (17.7%, p=0.02).     
 
Overall Findings.  Table 7 shows the ORs and 95% CIs for the main deployment exposures 
explored in this Aim.  There was no association between overall deployment and HDP 
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(OR=1.03, 95% CI: 0.96-1.09), and the OR remained unchanged after adjustment for 
covariates. Similarly, we observed a very weak association between deployment ending ≥12 
months before birth and HDP that approached statistical significance (OR=1.06, 95% CI: 0.99-
1.15), but it moved away from this when adjusting for our covariates.  There was no association 
for deployments ending <12 months before birth, with the crude and adjusted ORs being equal 
(OR=0.97, 95% CI: 0.88-1.07).  For each one month increase in cumulative pre-birth 
deployment duration, there was an estimated 1% increased risk of any HDP, and this finding 
almost reached statistical significance even after adjusting for all covariates (OR=1.01, 95% CI: 
0.99-1.02).  We did not observe any association between timing of conception relative to 
deployment and HDP. 
 
Racial/Ethnic Findings.  Examination of the three main deployment exposures by racial/ethnic 
group produced similar results as the overall cohort, and crude ORs and 95% CIs remained 
unchanged when adjusting for covariates (Table 8).  The notable exception was among 
deployed black mothers, who experienced a 13% increased risk of HDP compared to blacks 
who did not deploy (OR=1.13, 95% CI: 1.00-1.27).  Mothers of other race had a similar risk, but 
it was not significant (OR=1.09, 95% CI: 0.87-1.36).  The observed risk between deployment 
and HDP among whites trended towards protective, but it was also statistically non-significant 
(OR=0.94, 95% CI: 0.86-1.03).   
 
When examining the timing of deployment end date relative to birth, the only statistically 
significant finding was among black mothers whose last deployment ended ≥12 months before 
birth.  Those women experienced an 18% increased risk of HDP compared to non-deployed 
black women (OR=1.18, 95% CI: 1.03-1.36).  The risk dropped to 8% among black mothers 
who gave birth within a year of their last deployment ending, and less than a 10% increased risk 
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was also observed for Hispanic and other race mothers for either deployment end date.  Again, 
although the relationship was not statistically significant, white mothers with either deployment 
end date were slightly protected against HDP compared to non-deployed white mothers.  There 
was very little increased risk of HDP for each additional month of cumulative deployment among 
each racial/ethnic group.  There was no association among whites (OR=1.00, 95% CI: 0.99-
1.01).     
    
Other Sub-Analysis Findings.  We observed statistically significant independent associations 
between certain covariates and HDP in the adjusted models examined in this Aim (data not 
shown).  Specifically, maternal age ≥35 years conferred a consistent 75% increased risk of HDP 
compared to the youngest mothers, and mothers with pre-gestational diabetes were 2.5 times 
more likely to develop an HDP than mothers without this condition.  When we explored 
confounding by military date, we did not observe any change in the odds-ratios for any of the 
three deployment exposures.  However, we noticed that women who entered the military prior to 
2001 were about 10% less likely to develop an HDP compared to mothers who entered in 2001 
and after.  Further, single mothers who were never married at the time of birth experienced a 
similar lower risk compared to married mothers.  Enlisted mothers experienced a 30% greater 
risk of HDP than officers, and the association strengthened to 40% when restricting to deployed 
mothers only. Finally, women in the Army and Navy were about 20% less likely to develop any 
HDP compared to Air Force mothers.   
 
The relationship between deployment (yes vs. no) and the four individual HDPs was very similar 
to the previously discussed findings for HDP overall (Appendix 3, Table 1).  When examining 
timing of deployment ending relative to birth, we observed the risk of chronic and gestational 
hypertension was about 15% greater for women whose deployments ended ≥12 months prior to 
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birth compared to non-deployed women, but the results were not significant as shown in 
Appendix 3, Table 2.  While this was slightly higher than for HDP overall, there was no 
association between women with deployments ending at this time and either preeclampsia or 
unknown hypertension.  Women whose last deployment ended within a year before birth were 
seemingly protected against each HDP except for preeclampsia, where there was an estimated 
7% increased risk.  However, none of the findings were statistically significant.  The findings for 
cumulative months of deployment and each HDP sub-type were also consistent with the overall 
cohort previously discussed (Appendix 3, Table 3).        
 
Specific Aim 2 Classification Trees 
Descriptive Characteristics. Women were deployed for a cumulative average of 33.3 weeks 
(±20.7) or just over 7.5 months during their military service before giving birth, with an average 
of 16.5% (±9.7) of the study period spent deployed as shown in Table 9.  No differences were 
observed between mothers with HDP and those without.  The average dwell time between the 
last two pre-birth deployments was 59.6 weeks (±40.3), or just under 14 months.  The average 
dwell time ratio was 0.77 (±1.3), indicating that most deployers had a longer dwell time than the 
previous deployment lasted.  Again, no significant difference was observed between HDP and 
non-HDP mothers. 
 
Classification Tree Findings.  The only meaningful classification trees were observed for 
cumulative weeks of deployment as it related to maternal age at birth and maternal 
race/ethnicity.  Figure 2 illustrates the tree created for maternal age, with the first cut occurring 
at 52 weeks of cumulative deployment, and then at maternal age 34 years.  We categorized the 
deployment variable into <1 year and ≥1 year of cumulative deployment, maternal age into <35 
years old and ≥35 years old, and race into black vs. all others.  The results of multivariable 
logistic regression are shown in Table 10.  Women who had a year or more of cumulative 
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deployment during the study period before birth were 17% more likely to develop an HDP than 
women with less deployment time (OR=1.17, 95% CI: 1.01-1.36).  This relationship remained 
among women under 35 years old (OR=1.16, 95% CI: 1.00-1.36), and it strengthened to 35% 
among women 35 years and older but the result was not statistically significant, perhaps due to 
low power of this small subgroup (OR=1.35, 95% CI: 0.74-2.47).  Black women with ≥1 year of 
cumulative deployment had a 19% increased likelihood of an HDP that approached statistical 
significance (OR=1.19, 95% CI: 0.98-1.42), but the risk among other races was only slightly 
lower (OR=1.14, 95% CI: 0.90-1.45).       
 
Specific Aim 3 PTSD 
Descriptive Characteristics: PTSD among the Entire Cohort. The overall prevalence of 
confirmed PTSD was 1.6% (Table 11).  Table 12 shows there was no significant difference in 
HDP incidence between women with confirmed PTSD and non-cases in the complete cohort 
(14.4% vs. 13.4%, p=0.47).  Although women with both PTSD and deployment history had the 
highest incidence of HDP (14.9% vs. 13.3% for neither), the rates did not differ significantly 
(p=0.70).  There were also no notable racial/ethnic differences in the overall prevalence of 
confirmed PTSD (data not shown), but confirmed PTSD cases among women identifying as 
other race had over twice the incidence of HDP as non-PTSD cases (25.5% vs. 11.7%, 
p=0.0004).       
 
Descriptive Characteristics: PDHA Mothers. We explored demographic characteristics 
among the 8,801 women who completed a PDHA in Table 13.  Compared to the overall cohort, 
a similar proportion of PDHA mothers were under 30 years old (86.3% vs. 88.6%), and the 
distribution was similar across racial/ethnic groups.  We noted that more mothers who 
completed a PDHA entered the military prior to 2001 (37.3% vs. 28.5%), more mothers were in 
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the Army (46.9% vs. 37.8%), and the proportion of mothers with confirmed PTSD was slightly 
higher (2.1% vs. 1.6%).   
 
A similar proportion of PDHA mothers had an HDP as compared to the overall cohort (13.7% vs. 
13.4%), and PDHA mothers older than 35 years old had the highest incidence of HDP (19.5%, 
p=0.004) as shown in Table 14.  Among women who completed a PDHA, black mothers had the 
highest incidence of HDP (17.2%, p<0.0001).  This was slightly higher than for black mothers in 
the overall cohort (15.7%).  We observed no other statistically significant differences in HDP 
incidence for other covariates among PDHA mothers.  Overall, there was consistency between 
the entire cohort and PDHA mothers when examining the proportion of HDP sub-types overall 
and by race/ethnicity, with the exception of Hispanic mothers experiencing less preeclampsia 
than overall (Table 15).   
 
We also studied demographics for the 808 mothers missing PDHA responses (Appendix 3, 
Table 4).  Among mothers with missing data, we discovered that a slightly higher proportion 
were older than those without missing data (22.5% vs. 13.8%), the proportion of Hispanics was 
slightly lower (11.7% vs. 15.7%), and the proportion of whites slightly greater (55.4% vs. 
47.7%).  More women with missing data were married (75.7% vs. 64.7%), were officers (15.4% 
vs. 11.9%), in the Air Force (68.7% vs. 24.9%), and entered military service after 2001 (82.6% 
vs. 62.7%).  Mothers with missing data had no confirmed PTSD cases and were more likely to 
have deployed to Kosovo (4.7% vs. 0.4%).       
 
Descriptive Characteristics: PTSD among PDHA Mothers. Tables 16 and 17 quantify the 
distribution of our PTSD variables for PDHA mothers.  Using the ≥3 case-definition, the overall 
prevalence of any PTSD was 6.2%.  Very few women had possible PTSD (n=33, 0.4%), while 
3.5% were classified as probable (n=279), and 2.3% were confirmed (n=187).  When relaxing 
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the case-definition to the ≥2 criteria, an additional 25 mothers were added to the possible 
category (n=58, 0.7%) and 257 added to the probable category (n=536, 6.7%), bringing the 
overall prevalence to 9.7%.  Women in the ≥3 probable category had the highest incidence of 
HDP (16.1%), followed by possible (15.2%), confirmed (14.4%), and none (13.7%), and the 
difference was significant (p<0.0001).  The overall pattern was the same using the ≥2 criteria, 
but the differences were not statistically significant (p=0.38).  Patterns across racial/ethnic 
groups were similar (data not shown).  A total of 2,419 (77%) PDHRAs were matched to a 
PDHA using the ≥3 case-definition, and the result was almost identical using the ≥2 method 
(n=2,428, 77.3%).  Only 103 (4.3%) of women were positive on a PDHA (defined as possible or 
probable) but were negative on a PDHRA.  The number increased only slightly to 163 (6.7%) 
using the ≥2 definition.        
 
Overall Findings.  Out of the entire cohort, mothers with confirmed PTSD experienced a 9% 
increased risk of HDP compared to non-PTSD mothers (OR=1.09, 95% CI: 0.86-1.39) as Table 
18 shows, and the relationship strengthened slightly to a 15% increased risk for mothers with 
any PTSD (OR=1.15, 95% CI: 0.95-1.39).  The latter finding also approached statistical 
significance.  When exploring effect modification by deployment, the risk was virtually the same 
among deployed (OR=1.10, 95% CI: 0.77-1.57) and non-deployed (OR=1.08, 95% CI: 0.78-
1.49) women with confirmed PTSD vs. women without PTSD.  However, when using the 
expanded PTSD definition (any PTSD), the association among deployed women with PTSD 
strengthened slightly, so that deployed women with any PTSD were at 18% greater risk of HDP 
than women who did not have PTSD (OR=1.18, 95% CI: 0.93-1.50).  Increased risk among non-
deployed mothers with any PTSD remained at 8% (OR=1.08, 95% CI: 0.78-1.49).  This 
represented an approximate 9% increase in HDP risk for deployed mothers with PTSD vs. those 
without PTSD compared to non-deployed PTSD mothers.   
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Overall Sub-Analysis Findings.  Overall, women with any PTSD across racial categories 
experienced a higher risk of HDP compared to women without PTSD (Appendix 3, Table 5).  
White (OR=1.08, 95% CI: 0.84-1.41) and black (OR=1.08, 95% CI: 0.74-1.59) mothers had the 
same and smallest elevated risk (both 8%), followed by a 16% higher risk among Hispanics 
(OR=1.16, 95% CI: 0.65-2.10), and nearly 90% higher risk of HDP among PTSD mothers 
identifying as other race (OR=1.87, 95% CI: 1.05-3.34).  The latter group is the only one that 
achieved statistical significance.  When examining the relationship between any PTSD and 
specific HDP sub-types as shown in Appendix 3, Table 6, we noted the risk of chronic 
hypertension and preeclampsia was approximately 10%, followed by a 24% increased risk of 
gestational hypertension, and a 72% increased risk of unknown hypertension compared to non-
PTSD mothers.  No category was statistically significant.    
 
Overall Findings: PDHA Mothers.  Table 19 illustrates the relationship between case-definition 
levels of PTSD and HDP overall and by racial/ethnic group among mothers who completed a 
PDHA.  Interestingly, women in the possible and probable categories experienced the same 
magnitude of risk of HDP (OR=1.21, 95% CI: 0.46-3.16 and OR=1.22, 95% CI: 0.87-1.72, 
respectively), and it was higher than the risk experienced by women with confirmed PTSD 
(OR=1.05, 95% CI: 0.68-1.62) in the fully adjusted models.  When relaxing the case-definition to 
the ≥2 criteria, risk among women in the possible category was attenuated to match mothers in 
the confirmed category (OR=1.03, 95% CI: 0.46-2.29 and OR=1.06, 95% CI: 0.69-1.64, 
respectively), while HDP risk among women in the probable group was higher at 30% compared 
to mothers without any PTSD (OR=1.30, 95% CI: 1.01-1.67).  
 
The analysis assessing the relationship among PTSD levels and HDP from the PDHRA only 
was not more informative, and no findings were statistically significant (Appendix 3, Table 7).  
Using the ≥3 case-definition, confirmed mothers were 1.45 times more likely to develop HDP 
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(OR=1.45, 95% CI: 0.77-2.272) vs. 1.05 times more likely on the PDHA, probable mothers were 
1.23 times more likely (OR=1.23, 95% CI: 0.79-1.92) vs. 1.22 times more likely on the PDHA, 
and possible mothers 0.91 were times less likely to develop HDP (OR=0.91, 95% CI: 0.27-3.11) 
vs. 1.21 times more likely on the PDHA compared to mothers without PTSD. The ORs for the 
confirmed (OR=1.32, 95% CI: 0.67-2.59) and probable (OR=1.14, 95% CI: 0.79-1.63) groups 
were attenuated when relaxing the case-definition, but the OR among the possible group 
changed direction and became a risk factor (OR=1.41, 95% CI: 0.74-2.69).   
 
Racial/Ethnic Findings: PDHA Mothers. The observed findings were not consistent across 
racial/ethnic groups, and the only significant finding was among other race women (Table 19).  
The pattern among white mothers was closest to the overall but differed slightly.  Mothers with 
confirmed PTSD experienced the lowest risk of HDP which was also seemingly protective 
(OR=0.84, 95% CI: 0.47-1.53), with probable mothers experiencing the highest risk (OR=1.30, 
95% CI: 0.77-2.20).  Relaxing the case-definition strengthened the probable PTSD association 
but attenuated the OR among the possible PTSD group.  Among black women, we observed a 
24% reduced risk of HDP in the confirmed PTSD group (OR=0.76, 95% CI: 0.29-1.99), with 
probable PTSD mothers 8% (OR=1.08, 95% CI: 0.61-1.89) more likely to develop HDP and 
possible PTSD mothers 32% (OR=1.32, 95% CI: 0.28-6.29) more likely to develop HDP.  
Similar to whites, using the ≥2 case-definition strengthened the association for probable PTSD 
mothers, but actually caused the possible OR to change direction and become protective.  
Confirmed PTSD (OR=1.79, 95% CI: 0.50-6.41) and probable PTSD (OR=1.95, 95% CI: 0.79-
4.86) Hispanic mothers were both at higher risk of HDP with more extreme associations than 
whites or blacks, but the OR among probable PTSD women instead weakened using the 
relaxed case-definition.  There were no Hispanics who met the case-definition for possible 
PTSD.  Among other race mothers, those with confirmed PTSD experienced 6.62 times the risk 
of HDP compared to mothers without PTSD (OR=6.62, 95% CI: 1.72-25.47), but probable 
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PTSD mothers experienced nearly 30% lower risk of HDP (OR=0.71, 95% CI: 0.15-3.31).  The 
confirmed relationship remained when exploring the ≥2 criteria while the probable was 
attenuated.       
    
HDP Sub-Type Findings: PDHA Mothers.  We were not able to assess the relationship 
between PTSD using the case-definition method and either chronic hypertension or unknown 
hypertension.  There were too few cases across some strata to fit the logistic model.  However, 
we noted increasing risk as the case-definition became more stringent using the ≥3 criteria for 
our gestational hypertension outcome as shown in Appendix 3, Table 8.  There was no 
association between confirmed PTSD and gestational hypertension (OR=1.01, 95% CI: 0.51-
2.01), but women with probable PTSD experienced 1.69 times the risk of gestational 
hypertension compared to non-PTSD women (OR=1.69, 95% CI: 1.04-2.76), increasing to 2.18 
times the risk of HDP among possible mothers (OR=2.18, 95% CI: 0.65-2.76).  Both the 
probable and possible associations were attenuated when relaxing the case-definition, with 
probable PTSD mothers experiencing the greatest risk out of the categories (OR=1.58, 95% CI: 
1.08-2.32).  The pattern was less clear for our preeclampsia group, and there were no 
significant findings.   
 
PDHRA Agreement Sub-Analysis Findings: PDHA Mothers.  Overall, women with positive 
agreement between their PDHA and PDHRA (OR=1.31, 95% CI: 0.56-3.06) or who became 
positive on their PDHRA (OR=1.19, 95% CI: 0.65-2.17) were at increased risk of HDP using the 
≥3 case-definition whereas there was essentially no association among women who were 
initially positive on their PDHA and negative on their PDHRA (OR=0.96, 95% CI: 0.54-1.71) as 
illustrated in Appendix 3, Table 9.  However, none of the observed associations were 
statistically significant.  Associations for the positive-positive and negative-positive groups were 
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attenuated when examining the ≥2 case-definition criteria, with an association remaining only for 
positive-positive mothers (OR=1.18, 95% CI: 0.63-2.20). 
 
Timing of Conception Sub-Analysis Findings: Entire Cohort & PDHA Mothers.  Table 20 
shows that mothers across the entire cohort with confirmed PTSD diagnosed between 
conception and birth (OR=0.87, 95% CI: 0.49-1.56) or diagnosed within a year before 
conception (OR=0.72, 95% CI: 0.46-1.11) were seemingly protected against HDP compared to 
mothers without PTSD.  However, mothers who were diagnosed with confirmed PTSD a year or 
more prior to conception were 55% more likely to develop HDP (OR=1.55, 95% CI: 1.09-2.20).  
When restricting to PDHA mothers using the ≥3 PTSD screening definition, only mothers 
diagnosed within a year before conception were protected (OR=0.38, 95% CI: 0.12-1.21), while 
the other two categories increased risk by approximately 20% compared to non-PTSD mothers.  
None of the findings among PDHA-only mothers were statistically significant.    
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Table 2. Frequency of Main Exposures and Covariates for the 
Entire Cohort, n=36,675.1 
  
Total Military 
n % % 
Maternal Age at Birth 
  18 to 24 years 23,969 65.4 40% 
  25 to 29 years 8,524 23.2 
60%   30 to 34 years 3,017 8.2 
  ≥35 years 1,165 3.2 
Maternal Race 
  White 18,071 50.3 53.0 
  Black 9,291 25.9 31.0 
  Hispanic 5,229 14.6 13.0 
  Other2,3 3,343 9.3 11.0 
  Missing 741 2.0  
Marital Status at Birth 
  Married 23,861 65.1 46.0 
  Single, never married 11,773 32.1 Unk 
  Other 1,002 2.7 Unk 
  Missing 39 0.1  
Pay Grade at Birth 
  Officer 4,037 11.0 17.0 
  Enlisted 32,638 89.0 83.0 
Pre-Gestational Diabetes 
  Yes 40 0.1  
  No 36,635 99.9  
Entry to Military Before 2001 
  Yes 9,936 28.5  
  No 24,983 71.6  
  Missing 1,756 4.8  
Confirmed PTSD 
  Yes 569 1.6  
  No 36,106 96.5  
Deployed 
  Yes 12,828 35.0 50.0 
  No 23,847 65.0 50.0 
 
1Missing values were not included in calculated percents or p-values. 
2Other race included Asian, American Indian, and DOD "Other" category. 
3Military totals do not add to 100 because estimates separated race from 
Hispanic ethnicity.  
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Table 3. Frequency of Main Exposures and Covariates by HDP 
Status for the Entire Cohort, n=36,675.1 
  
HDP p-value
2 
n=4,907 
13.4% 
n % 
 
Maternal Age at Birth 
  18 to 24 years 3,135 13.1 
<0.0001 
  25 to 29 years 1,135 13.3 
  30 to 34 years 414 13.7 
  ≥35 years 223 19.1 
Maternal Race 
  White 2,435 13.5 
<0.0001 
  Black 1,457 15.7 
  Hispanic 520 9.9 
  Other3 396 11.9 
  Missing 99 13.4   
Marital Status at Birth 
  Married 3,238 13.6 
0.29   Single, never married 1,527 13.0 
  Other 134 13.4 
  Missing 8 20.5   
Pay Grade at Birth 
  Officer 497 12.3 
0.03 
  Enlisted 4,410 13.5 
Pre-Gestational Diabetes 
  Yes 12 30.0 
0.002 
  No 4,895 13.4 
Entry to Military Before 2001 
  Yes 1,358 13.7 
0.43 
  No 3,334 13.4 
  Missing 215 12.2   
Confirmed PTSD 
  Yes 82 14.4 
0.47 
  No 4,825 13.4 
Deployed 
  Yes 1,739 13.6 
0.47 
  No 3,168 13.3 
1Missing values were not included in calculated percents or p-values. 
2P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a 
cell <5) using a 5% significance level. 
3Other race included Asian, American Indian, and DOD "Other" category. 
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Table 4. Frequency of HDP Sub-types Overall and by Race, Entire Cohort. 
  
Total Whites Blacks Hispanic Other 
n=36,675 n=18,071 n=9,291 n=5,229 n=3,343 
n % n % n % n % n % 
Any HDP 4,907 13.4 2,435 13.5 1,457 15.7 520 9.9 396 11.9 
Chronic Hypertension1 465 9.5 214 8.8 176 12.1 35 6.7 29 7.3 
Gestational Hypertension 1,610 32.8 903 37.1 401 27.5 144 27.7 128 32.3 
Preeclampsia 2,700 55.0 1,249 51.3 844 57.9 332 63.8 225 56.8 
Unknown Hypertension 132 2.7 69 2.8 36 2.5 9 1.7 14 3.5 
 
1Chronic hypertension included 8 women coded as having pre-gestational chronic hypertension without any diagnosed HDP. 
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Table 5. Frequency of Main Deployment Exposures and Covariates, Specific Aim 1.1 
  
Total Military 
n % % 
Deployed (n=36,675) 
  Yes 12,828 35.0 50.0 
  No 23,847 65.0 50.0 
Number of Deployments (n=36,108)2 
  0 23,847 66.0  
  1 9,740 27.0  
  2 2,109 5.8  
  ≥3 412 1.1  
Timing of Deployment End Relative to Birth (n=36,108)2 
  Non-deployed 23,847 66.0  
  Ended ≥12 months before birth 7,740 21.4  
  Ended <12 months before birth 4,521 12.5  
Timing of Deployment Relative to Estimated Conception Date (n=35,843)2 
  Non-deployed 23,847 66.5  
  Before Deployment Started 399 1.1  
  During Deployment 1,957 5.5  
  After Deployment Ended 9,640 26.9  
  Missing Gestational Age 265 0.7  
Branch (n=12,261)2,3 
  Air Force 2,824 23.0 31.0 
  Army 4,631 37.8 37.0 
  Navy4 4,806 39.2 32.0 
Occupation (n=11,939)2,3 
  Combat 1,264 10.6 15.0 
  Healthcare 1,275 10.7 15.0 
  Other 9,400 78.7 70.0 
  Missing 322 2.6  
Deployment Location (n=12,261)2,3 
  Kosovo Only 40 0.3  
  Southwest Asia Only 26 0.2  
  OEF/OIF Only 12,116 98.8  
  Other5 79 0.6  
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Table 5. Frequency of Main Deployment Exposures and Covariates, Specific Aim 1 
(Continued).1 
 
 
Cumulative Weeks of Deployment (n=12,261)2,3 
  Mean±Std. dev. 33.3±20.7 
 
1Missing values are not included in calculated percents. 
2Women missing from the original deployment database but who completed a PDHA or PDHRA and 
women with overlapping deployment dates were excluded (n=567). 
3Included deployed mothers only. 
4Navy included the Marines and Coast Guard. 
5Other included Kosovo and OEF/OIF, Southwest Asia and OEF/OIF. 
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Table 6. Frequency of Main Deployment Exposures and Covariates by HDP 
Status, Specific Aim 1.1 
  
HDP p-value
2 
n % 
 
Deployed (n=36,675) 
  Yes 1,739 13.6 
0.47 
  No 3,168 13.3 
Number of Deployments (n=36,108)3 
  0 3,168 13.3 
0.93 
  1 1,311 13.5 
  2 299 14.2 
  ≥3 57 13.8 
Timing of Deployment End Relative to Birth (n=36,108)3 
  Non-deployed 3,168 13.3 
0.21   Ended ≥12 months before birth 1,081 14.0 
  Ended <12 months before birth 586 13.0 
Timing of Deployment Relative to Estimated Conception Date (n=35,843)3 
  Non-deployed 3,168 13.3 
0.50 
  Before Deployment Started 53 13.3 
  During Deployment 241 12.3 
  After Deployment Ended 1,310 13.6 
  Missing Gestational Age 63 23.8   
Branch (n=12,261)3,4 
  Air Force 435 15.4 
<0.0001   Army 627 13.5 
  Navy5 605 12.6 
Occupation (n=11,939)3,4 
  Combat 145 11.5 
0.01   Healthcare 198 15.5 
  Other 1,279 13.6 
  Missing 45 14.0   
Deployment Location (n=12,261)3,4 
  Kosovo Only 4 10.0 
0.77 
  Southwest Asia Only 5 19.2 
  OEF/OIF Only 1,648 13.6 
  Other6 10 12.7 
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Table 6. Frequency of Main Deployment Exposures and Covariates by HDP 
Status, Specific Aim 1 (Continued).1 
 
Cumulative Weeks of Deployment (n=12,261)3,4 
  p-value2 
  Mean±Std. dev. 33.9±20.9 0.24 
 
1Missing values are not included in calculated percents. 
2P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a cell <5) for 
categorical variables and t-tests for continuous variables using a 5% significance level. 
3Women missing from the original deployment database but who completed a PDHA or 
PDHRA and women with overlapping deployment dates were excluded (n=567). 
4Included deployed mothers only. 
5Navy included the Marines and Coast Guard. 
6Other included Kosovo and OEF/OIF, Southwest Asia and OEF/OIF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
 
Table 7. Odds-ratios and 95% Confidence Intervals for Overall Deployment 
Measures and HDP, Specific Aim 1.1 
  
Crude      
OR 
95% CI 
Adjusted 
OR 
95% CI 
Deployed vs. Non-Deployed (n=35,897)2 
  No 1.00 1.00 
  Yes 1.03 0.96-1.09 1.02 0.95-1.09 
Timing of Deployment Ending Relative to Birth (n=35,337)2,3 
  Non-Deployed 1.00 1.00 
  Ended ≥12 months before birth 1.06 0.99-1.15 1.05 0.97-1.13 
  Ended <12 months before birth 0.97 0.88-1.07 0.97 0.88-1.07 
Cumulative Weeks of Deployment (n=11,685)3,4 
  For each 1 month increase 1.01 0.99-1.02 1.01 0.99-1.02 
Timing of Conception (n=35,617)2,3,5 
  Non-Deployed 1.00 1.00 
  Before Deployment Started 1.01 0.75-1.35 1.01 0.75-1.36 
  During Deployment 0.92 0.80-1.06 0.92 0.80-1.06 
  After Deployment Ended 1.02 0.96-1.10 1.01 0.92-1.09 
 
1Women with missing values for any covariates were not included in regression models. 
2Adjusted logistic models include maternal age at birth, maternal race, marital status at birth, pay 
grade at birth, and pre-gestational diabetes. 
3Women missing from the original deployment database but who completed a PDHA or PDHRA 
and women with overlapping deployment dates were excluded (n=567). 
4Logistic models included deployed women only and adjusted models include covariates used in 
previous models in addition to branch and occupation. 
5Records missing gestational age were excluded. 
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Table 8. Odds-ratios and 95% Confidence Intervals for Overall Deployment Measures and HDP by Racial Category, Specific Aim 1.1 
  
White Black Hispanic Other2 
Adjusted 
OR 
95% CI 
Adjusted 
OR 
95% CI 
Adjusted 
OR 
95% CI 
Adjusted 
OR 
95% CI 
Deployed vs. Non-Deployed3  n=18,039 n=9,264  n=5,220  n=3,334  
  No 1.00 1.00 1.00 1.00 
  Yes 0.94 0.86-1.03 1.13 1.00-1.27 1.04 0.86-1.26 1.09 0.87-1.36 
Timing of Deployment Ending 
Relative to Birth3,4 
n=17,766  n=9,129  n=5,123  n=3,279  
  Non-Deployed 1.00 1.00 1.00 1.00 
  Ended ≥12 months before birth 0.98 0.87-1.09 1.18 1.03-1.36 1.06 0.84-1.33 1.07 0.82-1.39 
  Ended <12 months before birth 0.88 0.76-1.02 1.08 0.91-1.27 1.04 0.80-1.36 1.06 0.75-1.48 
Cumulative Weeks of Deployment4,5  n=5,462 n=3,321 n=1,823  n=1,069 
  For each 1 month increase 1.00 0.99-1.01 1.003 0.99-1.01 1.003 0.99-1.01 1.004 0.99-1.01 
 
1Women with missing values for any covariates were not included in regression models. 
2Other race included Asian, American Indian, and DOD "Other" category. 
3Adjusted logistic models include maternal age at birth, marital status at birth, and pay grade at birth. 
4Women missing from the original deployment database but who completed a PDHA or PDHRA and women with overlapping deployment dates were excluded 
(n=567). 
5Logistic models included deployed women only and adjusted models include covariates used in previous models in addition to branch and occupation. 
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Table 9. Frequency of Main Exposures and Covariates by HDP Status for 
Deployed Women Only, Specific Aim 2.1 
  Total HDP p-value
2 
Cumulative Weeks of Deployment (n=12,261) 
  Mean±Std. dev. 33.3±20.7 33.9±20.9 0.24 
Percent of Time Spent Deployed in Study Period Before Birth (n=11,589)3 
  Mean±Std. dev. 16.5±9.7 16.4±10.0 0.89 
Dwell Time (in weeks) (n=2,521)4 
  Mean±Std. dev. 59.6±40.3 60.2±38.7 0.74 
Dwell Time Ratio (n=2,521)4,5 
  Mean±Std. dev. 0.77±1.3 0.70±1.0 0.37 
 
1Women missing from the original deployment database but who completed a PDHA or 
PDHRA and women with overlapping deployment dates were excluded (n=567). 
2P-values are for t-tests using a 5% significance level. 
3Excludes women missing military entry time or with entry time errors. 
4Includes women who completed >1 deployment. 
5Dwell time ratio is calculated as the length of the second most recent pre-birth deployment 
divided by the length of break time between the two most recent pre-birth deployments. 
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Figure 2. Classification Tree for Cumulative Weeks of Deployment by Maternal Age. 
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Table 10. Odds-ratio and 95% Confidence Intervals for Categorized 
Cumulative Weeks of Deployment among Deployed Women Only, Specific 
Aim 2, n=11,685.1,2,3 
  OR 95% CI 
Cumulative Weeks of Deployment 
  <1 year 1.00 
  ≥1 year 1.17 1.01-1.36 
Interaction with Age 
<35 Years Old 
  ≥1 year vs. <1 year cumulative deployment 1.16 1.00-1.36 
≥35 Years Old 
  ≥1 year vs. <1 year cumulative deployment 1.35 0.74-2.47 
Interaction with Race 
Black 
  ≥1 year vs. <1 year cumulative deployment 1.19 0.98-1.42 
All Other Races4 
  ≥1 year vs. <1 year cumulative deployment 1.14 0.90-1.45 
 
1Women missing from the original deployment database but who completed a PDHA or 
PDHRA and women with overlapping deployment dates were excluded (n=567). 
2ORs are adjusted for maternal age at birth, maternal race, marital status at birth, pay 
grade, branch, and occupation. 
3Women with missing values for any covariates were not included in regression models. 
4Other race includes White, Hispanic, Asian, American Indian, and DOD "Other" category. 
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Table 11. Frequency of PTSD Exposures for the Entire 
Cohort, Specific Aim 3, n=36,675. 
  
Total 
n % 
Confirmed PTSD 
  Yes 569 1.6 
  No 36,106 96.5 
Confirmed PTSD by Deployment Status 
  No PTSD/No Deployment         23,526 64.1 
  PTSD/No Deployment             321 0.9 
  No PTSD/Deployment         12,580 34.3 
  PTSD/Deployment             248 0.7 
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Table 12. Frequency of PTSD Exposures by HDP Status for the 
Entire Cohort, Specific Aim 3, n=36,675. 
  
HDP p-value
1 
n=4,907 
 
13.4% 
n % 
Confirmed PTSD 
  Yes 82 14.4 
0.47 
  No 4,825 13.4 
Confirmed PTSD by Deployment Status 
  No PTSD/No Deployment       3,123  13.3 
0.70 
  PTSD/No Deployment            45  14.0 
  No PTSD/Deployment       1,702  13.5 
  PTSD/Deployment            37  14.9 
1P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a cell 
<5) for categorical variables and t-tests for continuous variables using a 5% 
significance level. 
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Table 13. Frequency of Main Exposures and 
Covariates for PDHA Mothers Only, Specific Aim 3, 
n=8,801.1 
  
Total 
n % 
Maternal Age at Birth 
  18 to 24 years 4,919 55.9 
  25 to 29 years 2,673 30.4 
  30 to 34 years 902 10.3 
  ≥35 years 307 3.5 
Maternal Race 
  White 4,108 47.7 
  Black 2,398 27.8 
  Hispanic 1,350 15.7 
  Other2 758 8.8 
  Missing 187 2.1 
Marital Status at Birth 
  Married 5,684 64.7 
  Single, never married 2,724 31.0 
  Other 377 4.3 
  Missing 16 0.2 
Pay Grade at Birth 
  Officer 1,046 11.9 
  Enlisted 7,755 88.1 
Pre-Gestational Diabetes 
  Yes 7 0.1 
  No 8,794 99.9 
Entry to Military Before 2001 
  Yes 3,101 37.3 
  No 5,220 62.7 
  Missing 480 5.5 
Branch 
  Air Force 2,191 24.9 
  Army 4,129 46.9 
  Navy3 2,481 28.2 
Occupation 
  Combat 769 9.5 
  Healthcare 973 12.0 
  Other 6,337 78.4 
  Missing 722 8.2 
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Table 13. Frequency of Main Exposures and 
Covariates for PDHA Mothers Only, Specific Aim 3, 
n=8,801 (Continued).1 
 
 
Total 
n % 
Deployment Location 
  Kosovo Only 32 0.4 
  Southwest Asia Only 7 0.1 
  OEF/OIF Only 8,185 98.5 
  Other4 86 1.0 
  Missing 491 5.6 
Confirmed PTSD 
  Yes 187 2.1 
  No 8,614 97.9 
 
1Missing values are not included in calculated percents. 
2Other race includes Asian, American Indian, and DOD 
"Other" category. 
3Navy included the Marines and Coast Guard. 
4Other included Kosovo and OEF/OIF, Southwest Asia and 
OEF/OIF. 
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Table 14. Frequency of Main Exposures and Covariates by HDP 
Status for PDHA Mothers Only, Specific Aim 3, n=8,801.1 
  
HDP p-value
2 
n=1,201 
13.7% 
n % 
Maternal Age at Birth 
  18 to 24 years 646 13.1 
0.004 
  25 to 29 years 355 13.3 
  30 to 34 years 140 15.5 
  ≥35 years 60 19.5 
Maternal Race 
  White 539 13.1 
<0.0001 
  Black 413 17.2 
  Hispanic 134 9.9 
  Other3 88 11.6 
  Missing 27 14.4   
Marital Status at Birth 
  Married 802 14.1 
0.18   Single, never married 344 12.6 
  Other 52 13.8 
  Missing 3 18.8   
Pay Grade at Birth 
  Officer 126 12.1 
0.11 
  Enlisted 1,075 13.9 
Pre-Gestational Diabetes 
  Yes 2 28.6 
0.25 
  No 1,199 13.6 
Entry to Military Before 2001 
  Yes 430 13.9 
0.61 
  No 703 13.5 
  Missing 68 14.2   
Branch 
  Air Force 321 14.7 
0.06   Army 574 13.9 
  Navy4 306 12.3 
Occupation 
  Combat 862 12.1 
0.14   Healthcare 93 12.1 
  Other 149 15.3 
  Missing 97 13.4   
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Table 14. Frequency of Main Exposures and Covariates by HDP 
Status for PDHA Mothers Only, Specific Aim 3, n=8,801 
(Continued).1 
 
 
HDP p-value
2 
n=1,201 
13.7% 
n % 
Deployment Location 
  Kosovo Only 4 12.5 
1.00 
  Southwest Asia Only 1 14.3 
  OEF/OIF Only 1,122 13.7 
  Other5 12 14.0 
  Missing 62 12.6   
Confirmed PTSD 
  Yes 27 14.4 
0.75 
  No 1,174 13.6 
 
1Missing values are not included in calculated percents. 
2P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a 
cell <5) for categorical variables and t-tests for continuous variables using a 
5% significance level. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
4Navy included the Marines and Coast Guard. 
5Other included Kosovo and OEF/OIF, Southwest Asia and OEF/OIF. 
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Table 15. Frequency of HDP Sub-types Overall and by Race, PDHA Mothers Only, Specific Aim 3. 
  
Total Whites Blacks Hispanic Other 
n=8,801 n=4,108 n=2,398 n=1,350 n=758 
n % n % n % n % n % 
Any HDP 1,201 13.7 539 13.1 413 17.2 134 9.9 88 11.6 
Chronic Hypertension 122 10.2 51 9.5 49 11.9 12 9.0 8 9.1 
Gestational Hypertension 411 34.2 226 41.9 113 27.4 40 29.9 23 26.1 
Preeclampsia 638 53.1 252 46.8 242 58.6 78 58.2 52 59.1 
Unknown Hypertension 30 2.5 10 1.9 9 2.2 4 3.0 5 5.7 
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Table 16. Frequency of PTSD for PDHA Mothers Only, Specific Aim 3, n=8,801.1 
  n % 
PTSD (≥3 Case-Definition) 
  None 7,494 93.8 
  Possible 33 0.4 
  Probable 279 3.5 
  Confirmed 187 2.3 
  Missing 808 9.2 
PTSD (≥2 Case-Definition) 
  None 7,212 90.2 
  Possible 58 0.7 
  Probable 536 6.7 
  Confirmed 187 2.3 
  Missing 808 9.2 
PTSD Diagnosis Relative to Estimated Conception Date (≥3 Case-Definition) 
  No PTSD 7,494 93.9 
  Diagnosis between conception and birth 51 0.6 
  Diagnosis <1 year prior to conception 61 0.8 
  Diagnosis ≥1 year prior to conception 374 4.7 
  Missing Gestational Age 821 9.3 
PTSD Screening Agreement Between PDHA and PDHRA (≥3 Case-Definition) 
  Both Negative 2,140 88.5 
  Both Positive 37 1.5 
  Negative to Positive 87 3.6 
  Positive to Negative 103 4.3 
  One or Both Missing 52 2.2 
  PDHRA Did Not Match a PDHA 722 23 
PTSD Screening Agreement Between PDHA and PDHRA (≥2 Case-Definition) 
  Both Negative 1,989 81.9 
  Both Positive 77 3.2 
  Negative to Positive 148 6.1 
  Positive to Negative 163 6.7 
  One or Both Missing 51 2.1 
  PDHRA Did Not Match a PDHA 713 22.7 
 
1Missing values are not included in calculated percents. 
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Table 17. Frequency of PTSD by HDP Status for PDHA Mothers Only, Specific Aim 3, 
n=8,801.1 
  
HDP p-value
2 
n=1,201 
13.7% 
n % 
PTSD (≥3 Case-Definition) 
  None 1,026 13.7 
<0.0001 
  Possible 5 15.2 
  Probable 45 16.1 
  Confirmed 27 14.4 
  Missing 98 12.1   
PTSD (≥2 Case-Definition) 
  None 982 13.6 
0.38 
  Possible 7 12.1 
  Probable 87 16.2 
  Confirmed 27 14.4 
  Missing 98 12.1   
PTSD Diagnosis Relative to Estimated Conception Date (≥3 Case-Definition) 
  No PTSD 1,026 13.7 
0.07 
  Diagnosis between conception and birth 8 15.7 
  Diagnosis <1 year prior to conception 3 4.9 
  Diagnosis ≥1 year prior to conception 62 16.7 
  Missing Gestational Age 102 12.4   
PTSD Screening Agreement Between PDHA and PDHRA (≥3 Case-Definition) 
  Both Negative 338 15.8 
0.53 
  Both Positive 7 18.9 
  Negative to Positive 15 17.2 
  Positive to Negative 16 15.5 
  One or Both Missing 4 1.1 
  PDHRA Did Not Match a PDHA 104 14.4   
PTSD Screening Agreement Between PDHA and PDHRA (≥2 Case-Definition) 
  Both Negative 315 15.8 
0.64 
  Both Positive 13 16.9 
  Negative to Positive 22 14.9 
  Positive to Negative 25 15.3 
  One or Both Missing 4 7.8 
  PDHRA Did Not Match a PDHA 105 14.7   
 
1Missing values are not included in calculated percents. 
2P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a cell <5) for categorical variables 
and t-tests for continuous variables using a 5% significance level. 
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Table 18. Odds-ratio and 95% Confidence Intervals for PTSD, Entire 
Cohort, Specific Aim 3, n=35,897.1  
  
Confirmed PTSD Any PTSD 
OR 95% CI OR 95% CI 
PTSD2,3 
  No 1.00 1.00 
  Yes 1.09 0.86-1.39 1.15 0.95-1.39 
Interaction with Deployment 
Deployed 
  PTSD vs. none 1.10 0.77-1.57 1.18 0.93-1.50 
Non-Deployed 
  PTSD vs. none 1.08 0.78-1.49 1.08 0.78-1.49 
 
1Women with missing values for any covariates were not included in regression 
models. 
2Adjusted logistic models include maternal age at birth, maternal race, marital 
status at birth, pay grade at birth, and pre-gestational diabetes. 
3Crude OR did not change after adjustment for listed covariates. 
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Table 19. Odds-ratio and 95% Confidence Intervals for PTSD and HDP, Case-Definition Based on Screening among PDHA Mothers Only,  
Specific Aim 3.1 
  
Overall2 White3 Black Hispanic Other4 
n=7,261 n= 3,353 n=2,083 n=1,173 n=646 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
PTSD (≥3 Case Definition) 
  No PTSD 1.00 1.00 1.00 1.00 1.00 
  Confirmed 1.05 0.68-1.62 0.84 0.47-1.53 0.76 0.29-1.99 1.79 0.50-6.41 6.62 1.72-25.47 
  Probable 1.22 0.87-1.72 1.30 0.77-2.20 1.08 0.61-1.89 1.95 0.79-4.86 0.71 0.15-3.31 
  Possible 1.21 0.46-3.16 1.19 0.26-5.53 1.32 0.28-6.29 No cases 8.90 0.53-150.28 
PTSD (≥2 Case Definition) 
  No PTSD 1.00 1.00 1.00 1.00 1.00 
  Confirmed 1.06 0.69-1.64 0.86 0.47-1.56 0.77 0.30-2.01 1.79 0.50-6.41 6.69 1.74-25.76 
  Probable 1.30 1.01-1.67 1.41 0.97-2.07 1.21 0.80-1.84 1.40 0.69-2.83 0.95 0.32-2.88 
  Possible 1.03 0.46-2.29 1.07 0.31-3.68 0.79 0.18-3.56 0.77 0.10-6.05 4.38 0.38-50.37 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic model adjusted for maternal age at birth, maternal race, marital status at birth, pay grade at birth, pre-gestational diabetes, branch, and occupation. 
3Race-specific logistic models are adjusted for the same covariates as the overall model except for maternal race and pre-gestational diabetes.  Women with 
pre-gestational diabetes were excluded. 
4Other race includes Asian, American Indian, and DOD "Other" category. 
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Table 20. Odds-ratio and 95% Confidence Intervals for PTSD Diagnosis Relative to Timing of Conception and HDP, 
Specific Aim 3.1 
  
Confirmed PTSD2                   PTSD ≥33                PTSD ≥23                 
Entire Cohort PDHA Moms Only 
n=35,875 n=7,261 
OR 95% CI OR 95% CI OR 95% CI 
Timing of PTSD Diagnosis 
  No PTSD 1.00 1.00 1.00 
  PTSD diagnosed between conception and birth 0.87 0.49-1.56 1.19 0.55-2.55 1.01 0.60-1.70 
  PTSD diagnosed <1 year before conception 0.72 0.46-1.11 0.38 0.12-1.21 1.20 0.87-1.65 
  PTSD diagnosed ≥1 year before conception 1.55 1.09-2.20 1.23 0.91-1.65 1.24 0.88-1.73 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic model adjusted for maternal age at birth, maternal race, marital status at birth, pay grade at birth, and pre-gestational diabetes. 
3Logistic models are adjusted for the same covariates as the entire cohort model in addition to branch and occupation. 
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CHAPTER 5 
Discussion, Conclusions, and Recommendations 
 
 
Deployment and HDP   
Our study was the first to quantify the incidence of HDP among active-duty military women 
giving birth to their first child.  At just over 13%, the incidence was higher than among the 
general population where 5-10% of pregnancies are affected.21  This was an unexpected finding 
since active-duty military personnel are younger and healthier due to strict fitness standards, but 
supports the exploratory findings of Katon et al. who reported female veterans utilizing VA 
maternity benefits were 32% more likely to develop an HDP compared to the general population 
(SIR=1.32 95% CI: 1.15.-1.51).19  However, we found no association between overall 
deployment history and HDP.  Our results are supported by a study among U.S. Gulf War 
veterans that examined deployment during pregnancy compared to deployment at other times 
and its relationship with preterm birth and birth defects.  The authors reported no statistically 
significant associations with deployment in general, but they did find increased risk associated 
with maternal age greater than 35 years old (OR=1.45, 95% CI: 1.09-1.94).44  We also 
consistently observed elevated risk among our oldest mothers across our multivariable 
analyses, providing further evidence of older maternal age acting as a consistent risk factor for 
HDP.  The American College of Obstetricians and Gynecologists (ACOG) Task Force on 
Hypertension in Pregnancy cite maternal age over 35 or 40 years old as an independent risk 
factor for HDP.99  Overall, neither the timing of deployment ending relative to birth nor timing of 
deployment relative to conception contributed to the risk of HDP.  
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Black women in our study who had any deployment history and whose last deployment ended a 
year or more prior to birth did appear to experience a modest risk of HDP.  In a 2010 study of all 
North Carolina births between 1994 and 2003, Miranda et al. showed that black mothers had 
about twice the incidence of HDP compared to white mothers (20% vs. 11%), and the risk of 
HDP was greater for blacks across every age group.100  A comprehensive look at births in New 
York City from 1993 to 2002 revealed overall lower HDP incidence rates, but black mothers still 
carried the highest burden.101  If racial/ethnic disparities result from differential access to care, 
similar rates among racial/ethnic groups among the military population are expected.  Despite 
this theory, we identified a gap that could be explained by unmeasured sociodemograpic 
differences in our study that persisted even with presumably equal accessibility to health care.  
Such factors may include lower levels of social support, more sexual harassment during 
deployment, or specific stressful occupations.  Since there are about 2.5 times more black 
women in the U.S. military than in the U.S. general population (31% vs. 13%),5,102 it is 
imperative to understand and mitigate any extenuating circumstances that adversely impacts 
the health of black military women.      
 
We noticed a few other notable patterns.  We consistently observed that women who entered 
the military prior to 2001, those in the Navy or Marines, and single, never married women were 
seemingly protected against HDP.  The first two groups support the healthy warrior or healthy 
deployer effect that purports individuals who deploy are mentally and physically healthier than 
military personnel who do not.103,104  Our findings expand this concept to a healthy military effect 
where women who remain in the military for a long period of time tend to be healthier because 
they did not experience health problems expediting their discharge.  Further, individuals in the 
Army and Marine service branches are required to meet more rigorous physical training (PT) 
requirements due to the nature of their roles compared to the Air Force, likely decreasing the 
overall incidence of many health problems.  We hypothesize that single mothers experienced 
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less stress than married women in our cohort.  About 50% of married military women are 
married to another service member.5  Not only do married women in the general population 
experience poorer cardiovascular outcomes, the married women in our cohort may have felt 
particularly worried about a deployed partner in addition to their own military and normal life 
stresses.105       
 
Interestingly, we discovered that for each month of increasing cumulative deployment, the risk 
of HDP rose by 1% for the entire cohort, and our classification tree exploratory analysis helped 
us identify that cumulative deployment longer than one year increased the risk of HDP by 17% 
compared to deployed mothers with less than a year of cumulative deployment, especially 
among older mothers.  Exploring cut-points supported a critical dose-response relationship that 
we would have been missed by only looking at overall deployment status. On average, 
deployed women had less than a year of cumulative deployment (about 7.5 months), thus the 
overall association among the entire cohort might have been attenuated because the adverse 
effect of deployment was not observed until the one year mark.  More likely, though, it was 
attenuated due to the healthy warrior effect when comparing deployed women to a non-
deployed reference group. 
 
Our findings somewhat support those of previous authors investigating the relationship between 
deployment duration and adverse health outcomes.  Bleier et al. reported a general trend of 
worsening health outcomes associated with increasing months of deployment in the previous 
three years among troops, with the greatest risk occurring among individuals deployed 8 to 10 
months.  Individuals deployed 4 to 7 and >10 months experienced similar increased risk, but 
less than the 8 to 10 month group.55  This study was conducted among the Australian military, 
who may encounter different situations and care than the U.S. military.  Our findings for the 
exploration of etiologically relevant dwell times and dwell time ratios were not statistically 
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significant; however, our sample size was reduced considerably to about 2,500 women with >1 
deployment which may have reduced power significantly in that sub-analysis.  Since we could 
not locate any studies assessing the impact of these specific deployment measures on perinatal 
outcomes, further analytical research is warranted to more definitively elucidate whether or not a 
relationship exists.          
 
PTSD and HDP 
Our study filled an important gap by estimating the prevalence of PTSD among a large cohort of 
deployed military women in the post-9/11/2001 era.  The proportion of confirmed PTSD among 
our entire study population was 1.6%.  When integrating our screening case-definition among 
mothers who completed a PDHA, the proportion increased to 6.2% using the ≥3 criteria and to 
9.7% using the ≥2 criteria.  We noted a modest increase to 7.5% (≥3) and 11.7% (≥2) when 
examining only PDHRAs.  While our estimates are similar to existing studies assessing PTSD 
on the PDHA or PDHRA, they tended to be slightly different, perhaps due to different 
methodologies employed.   
 
Hoge et al. assessed the prevalence of PTSD using PDHAs among both men and women 
returning from OEF/OIF between 2003 and 2004, and reported 9.8% of OIF respondents 
endorsed two or more of the PTSD questions on the PDHA while only 4.7% of OEF 
respondents did.106  Our estimates were combined for returning OEF/OIF service personnel, 
and the overall prevalence using the ≥2 criteria was slightly higher than an average of the Hoge 
result (9.7% vs. 7.3%).  However, we also integrated additional “high risk” questions into our 
criteria that Hoge et al. did not use.  A later 2007 assessment revealed a similar level of PTSD 
as ours on the PDHA using both ≥3 and ≥2 criteria, but a higher prevalence of PTSD than we 
reported on the PDHRAs alone (9.1% using ≥3 and 16.7% using ≥2).  Their study population 
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was very different than our female cohort, with 90% being male, all in the Army, and most 
returning from combat-related positions.107  A DOD analysis of deployed personnel returning in 
2005 revealed a 10% PTSD prevalence using the ≥2 criteria on the PDHA among women which 
was similar to ours (9.7%).108    
 
We did not find any statistically significant findings when assessing the relationship between 
confirmed or any PTSD and HDP among the entire cohort.  However, relying on ICD-9-CM 
confirmed PTSD in the medical record likely misclassified positive mothers as negative and 
attenuated the association, as most mothers likely were not clinically diagnosed with PTSD 
even if they may have screened positive.  When expanding the definition to any PTSD, the OR 
for the overall relationship and the OR among deployed women strengthened and the lower 
bound of the confidence interval moved closer to statistical significance.  This indicates that 
mothers with PTSD may be at risk of having a pregnancy complicated by HDP, especially if they 
also deployed.  When restricting to mothers who deployed and completed a PDHA, we did find 
a 30% increased risk of HDP among probable PTSD cases using the ≥2 case-definition.  The 
probable PTSD group using the ≥3 case-definition followed a similar pattern, but did not achieve 
statistical significance likely due to a smaller sample size.   
 
We were surprised that we did not observe a strengthening dose-response trend when moving 
from probable to confirmed PTSD case status.  In fact, among all mothers who completed a 
PDHA overall, confirmed PTSD conferred a lower HDP risk than probable PTSD (≥3).  While 
this may have resulted from under detection of confirmed cases as previously discussed, 
differing diagnosis criteria could also explain the inconsistency.  We included additional PDHA 
screening questions related to depression and specific wartime experiences (firing a weapon, 
seeing dead bodies, etc.) to define our probable category.  Positive endorsement of these items 
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may indicate mental health conditions other than PTSD, such as anxiety disorders and 
depression.  It is possible that we detected an association between another type of mental 
health condition and HDP, or an interaction between PTSD and these conditions.          
 
We also noted that despite the very small sample size, mothers with confirmed PTSD and 
identifying as “other race” experienced a large, significant increased HDP risk.  It is difficult to 
interpret this result, as no clear patterns emerged among the other racial/ethnic groups.  Our 
original data from the DOD included an “other race” category to which Asian/Pacific Islander 
and American Indian women were added.  We can only speculate that the other category 
included women identifying as bi-racial, those of Middle Eastern descent, women who did not 
want to self-identify race, and women with another combination of race/ethnicity.  Also, 
inconsistent patterns across the other races may have resulted from unmeasured 
sociodemographic differences and/or differential medical follow-up.  A more specific 
racial/ethnic analysis should be conducted with detailed data.        
 
Women who conceived a year or more before their PTSD diagnosis (or positive screening) were 
at risk of HDP, which is opposite of the Shaw et al. study that found an increased risk of PTB 
among military women when diagnosis was made within a year before birth.64  We are unsure if 
our findings indicated a true association or was due to unmeasured confounding by an 
underlying fertility condition linked to HDP.  For example, polycystic ovarian syndrome effects 
approximately 8% of women in the general population, can cause infertility or delayed fertility, 
and is associated with a greater risk of later development of Type II diabetes and cardiovascular 
disease.109  Additionally, since we observed a protective association between diagnosis within a 
year of conception and HDP, there may have been under-diagnosis or attrition among this 
group.  Caution should be used interpreting this result.   
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Our study population included PTSD screenings for women who remained in the service post-
deployment long enough to have their first child, thus our data does not include women lost to 
attrition post-deployment who gave birth outside the military.  It is likely that some proportion of 
women with PTSD who would have been included in our study if they had remained in the 
military were missed, potentially underestimating the true number of PTSD cases.  Since it 
appears a relationship may exist between PTSD and HDP, our results may underestimate the 
true risk by missing these women.  Hoge et al. reported a slightly higher rate of military attrition 
within a year after completing a PDHA among individuals documenting mental health concerns 
compared to those not reporting any concerns (21% vs. 16%),106 demonstrating that less 
healthy individuals are likely to leave the military sooner.   
 
We may have also underestimated PTSD using the screening method because some service 
personnel provide false information on the PDHA to return home without additional medical 
referral.108  It is impossible to quantify the impact, but it is generally accepted that responses on 
the PDHRAs are more truthful.  The prevalence of PTSD did not increase substantially among 
the PDHRAs in our study population, therefore our findings using the PDHAs are likely only 
marginally underestimated due to this practice.  However, it may have impacted particular 
racial/ethnic groups differentially if extenuating socioeconomic or cultural drivers existed that 
influenced either how quickly an individual needed to return home after deployment, or which 
were acceptable responses.  Additionally, 808 (9.2%) of women completing a PDHA had 
missing responses for all of the variables we used to create our case-definition.  These women 
seemed more affluent, as they were slightly older, white, married officers, and more likely to be 
in the Air Force.  With a slightly lower rate of HDP and no confirmed PTSD cases among this 
group, the data was likely missing at random and did not impact our findings.  
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Overall Strengths and Weaknesses  
In addition to limitations previously discussed, we recognize that data on tobacco use was 
lacking; thus, we were unable to adjust for it as a potential confounder.  Previous studies have 
shown a reduced risk of HDP among smokers, a counterintuitive finding that is postulated to 
occur due to higher rates of early spontaneous miscarriage among smokers or due to a link 
between the genetic predisposition to smoke and HDP.110,111  Our observed results may be 
close to the null or even protective due to uncontrolled confounding by smoking in our cohort, 
especially since smoking is highly prevalent in the military.  About a quarter of the U.S. military 
were classified as current smokers in 2011 compared to 19% in the general population.84,112   
 
Additionally, we chose not to adjust for multiple comparisons in our study, and instead reported 
95% CIs with our OR estimates to let the reader make their own conclusions.  It is possible that 
some of our statistically significant findings were due to chance.  However, we carefully planned 
our hypotheses a priori and are confident they are based in scientific plausibility.  We did not 
wish to be too conservative and discourage further study among this often neglected portion of 
the U.S. Armed Forces.  Similarly, as Rothman purports, new scientific discoveries have been 
born of seemingly random findings that would have otherwise been missed if adjusting for 
multiple comparisons.113    
 
Our research did possess several strengths.  It was the first to include such a large number of 
military women in a study examining HDP as an outcome.  Our data included approximately 
36,000 first births, allowing us to explore two important exposures among this population, 
deployment and PTSD, with high statistical power.  Existing studies on deployment and adverse 
birth outcomes have lacked this level of power, which is likely responsible, at least in part, for 
the inconclusive findings.  Our study also included longitudinally collected records for our entire 
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study population, which eliminated the temporality issues some previous studies have 
encountered.   
 
Conclusions and Future Research 
We reported increasing risk of HDP among deployed black mothers and for cumulative 
deployment time longer than one year, in addition to increased risk associated with some levels 
of PTSD.  Future research is needed that includes more detailed demographic information for 
the entire cohort (i.e. smoking, race, occupation and branch), more specifics related to 
deployment experience, and PTSD screening information for all mothers.  If possible, 
quantifying deployment, PTSD and HDP among women who leave the military before having 
children should also be attempted to compare differences to those who remain in service.  
Based on our results, the military should explore the possibility of limiting cumulative 
deployment length to a year or less among women who wish to become pregnant, and may also 
wish to treat pregnant women who ever had signs or a diagnosis of PTSD as high risk maternity 
patients.  Also, drivers for the racial/ethnic disparities we observed should also be further 
explored and corrected.       
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APPENDIX 1: 
ICD-9-CM Codes Used to Define Variables in Methods Section 
 
Table 1. ICD-9-CM Procedure Codes for Live-Born Singleton Infants.  
 
Live, Singleton Birth V30.0 V30.00 V30.01 V30.1 V30.2 
Multiple Births and Unknown Plurality  
Twin, mate live-born V31.0 V31.00 V31.01 V31.1 V31.2 
Twin, mate stillborn V32.0 V32.00 V32.01 V32.1 V32.2 
Twin, unspecified V33.0 V33.00 V33.01 V33.1 V33.2 
Other multiple, all mates live-born V34.0 V34.00 V34.01 V34.1 V34.2 
Other multiple, all mates stillborn V35.0 V35.00 V35.01 V35.1 V35.2 
Other multiple, mates live and stillborn V36.0 V36.00 V36.01 V36.1 V36.2 
Other multiple, unspecified V37.0 V37.00 V37.01 V37.1 V37.2 
Unspecified V39.0 V39.00 V39.01 V39.1 V39.2 
 
Table 2. ICD-9-CM Diagnosis Codes for HDP. 
 
Chronic Hypertension 
642.00 642.01 642.02 642.03 642.04 
642.10 642.11 642.12 642.13 642.14 
642.20 642.21 642.22 642.23 642.24 
Gestational Hypertension 642.30 642.31 642.32 642.33 642.34 
Preeclampsia 
642.40 642.41 642.42 641.43 641.44 
642.50 642.51 642.52 641.53 641.54 
642.70 642.71 642.72 642.73 642.74 
Eclampsia 642.80 642.81 642.82 642.83 642.84 
Unspecified 642.90 642.91 642.92 642.93 642.94 
 
Table 3. ICD-9-CM Diagnosis Codes for Pre-Gestational Diabetes.  
 
250.00 250.01 250.02 250.03 
250.10 250.11 250.12 250.13 
250.20 250.21 250.22 250.23 
250.30 250.31 150.32 250.33 
250.40 250.41 250.42 250.43 
250.50 250.51 250.52 250.53 
250.60 250.61 250.62 250.63 
250.70 250.71 250.72 250.73 
250.80 250.81 250.82 250.83 
250.90 250.91 250.92 250.93 
 
89 
 
Table 4. ICD-9-CM Diagnosis Codes for Gestational Age.  
 
Unspecified weeks 765.20 
<24 weeks 765.21 
24 weeks 765.22 
25-26 weeks 765.23 
27-28 weeks 765.24 
29-30 weeks 765.25 
31-32  weeks 765.26 
33-34 weeks 765.27 
35-36 weeks 765.28 
≥37 weeks 765.29 
>40 to 42 weeks 766.21 
>42 weeks 766.22 
Extreme Immaturity 
765.00 765.01 765.02 765.03 
765.04 765.05 765.06 765.07 
765.08 765.09   
Other preterm infants 
765.10 765.11 765.12 765.13 
765.14 765.15 765.16 765.17 
765.18 765.19   
RDS 769    
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APPENDIX 2: 
Main Terms and Variable Definitions Used in Methods Section 
 
 
 
 
 
Table 1. Outcome Definition for Study. 
Hypertensive Disorders of Pregnancy (HDP) 
Definition: 
Any woman with ≥1 ICD-9-CM diagnoses in her birth 
hospitalization(s) records 
Variable Categories: 
0=None 
1=Yes 
Four sub-types of HDP defined and coded the same way:  
Chronic hypertension, Gestational hypertension, Preeclampsia, Unknown hypertension 
Table 2. Aim 1: Main Terms and Variable Definitions.  
Main Terms: 
Deployment. Assignment to a location that lacks a permanent U.S. military medical treatment 
facility outside the U.S. for >30 days, with current study examining post-9/11 era deployments. 
Main Variables: Categories: 
Deployed vs.  
Non-Deployed 
0=Non-Deployed 
1=Deployed 
Deployment Ending  
<12 months or  
≥12 months before birth 
0=Non-Deployed 
1=Deployment ended ≥12 months before birth 
2=Deployment ended <12 months before birth 
Cumulative Weeks of 
Deployment 
Continuous  
91 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Aim 1: Main Terms and Variable Definitions (Continued). 
Main Variables: Categories: 
Timing of Conception 
Relative to Deployment 
0=Non-Deployed 
1=Conception Before Deployment Started 
2=Conception During Deployment 
3=Conception After Deployment Ended 
 
Table 3. Aim 2: Main Terms and Variable Definitions. 
Main Variables: Definitions (all continuous): 
Cumulative Weeks of 
Deployment 
Total number of weeks each woman spent deployed within study 
period prior to birth 
Percent of Study Period 
Deployed 
Cumulative weeks of deployment divided by the total number of 
days spent in the military during the study period prior to birth 
Dwell Time (in weeks) 
Total number of weeks between the ending and beginning of the 
two most recent pre-birth deployments for women with >1 
deployment 
Dwell Time Ratio 
Duration in days of the second most recent pre-birth deployment 
divided by the dwell time in days between it and the most recent 
pre-birth deployment 
92 
 
Table 4. Aim 3: Main Terms and Variable Definitions. 
Main Terms: 
Post-Deployment Health Assessment (PDHA, Form DD2796). Administered within 30 days 
of deployment end to screen for potential mental health problems among troops returning 
home from deployment.  Used in the current study to define possible and probable PTSD. 
Post-Deployment Health Re-Assessment (PDHRA, Form DD2900). Administered 90-180 
days after the PDHA to screen for continuing or new mental health problems related to 
deployment. 
 
Health Assessment Screening Questions Used in PTSD Possible Case-Definition:  
(Yes / No) 
Have you ever had any experience that was so frightening, horrible, or upsetting that, IN THE 
PAST MONTH, you…  
1. Have had nightmares about it or thought about it when you did not want to? 
2. Tried hard not to think about it or went out of your way to avoid situations that remind 
you of it? 
3. Felt numb or detached from others, activities, or your surroundings? 
4. Were constantly on guard, watchful, or easily startled? 
 
Health Assessment Screening Questions Used in PTSD Probable Case-Definition: 
“High-Risk” (Yes / No) 
1. Did you see anyone wounded, killed, or dead during this deployment? 
2. Were you engaged in direct combat where you discharged your weapon? 
3. During this deployment, did you ever feel that you were in great danger of being killed? 
Depression (None, Some, A lot) 
1. Over the last 2 weeks (version 2003) or last month (version 2008), how often have you 
been bothered by any of the following problems? 
a. Little interest or pleasure in doing things 
b. Feeling down, depressed, or hopeless 
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Table 4. Aim 3: Main Terms and Variable Definitions (Continued). 
Main Variables: Categories: 
Confirmed PTSD 
0=No ICD-9-CM diagnoses for PTSD 
1=≥1 ICD-9-CM diagnoses for PTSD 
Any PTSD 
0= No ICD-9-CM diagnoses for PTSD 
1=≥1 ICD-9-CM diagnoses for PTSD or Possible/Probable 
screening on PDHA 
PTSD Case-
Definition 
(≥3 and ≥2) 
0=No indication of PTSD 
1=Confirmed 
2=Probable 
3=Possible 
Timing of PTSD 
Diagnosis Relative to 
Conception 
0=No indication of PTSD 
1=PTSD diagnosed between conception and birth 
2=PTSD diagnosed <1 before conception 
3=PTSD diagnosed ≥1 year before conception 
Pre-Post Comparison 
0=Both Negative 
1=Both Positive 
2=Negative to Positive 
3=Positive to Negative 
4=One or Both Missing 
 
Table 5. Additional Covariates: Main Terms and Variable Definitions. 
Variables: Categories: 
Maternal Age 
0=18 to 24 years 
1=25 to 29 years 
2=30 to 34 years 
3=≥35 years 
Maternal Race 
0=White 
1=Black 
2=Hispanic 
3=Other 
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Table 5. Additional Covariates: Main Terms and Variable Definitions (Continued). 
 
Variables: Categories: 
Marital Status at Birth 
0=Married 
1=Single, never married 
2=Other 
Pay Grade at Birth 
0=Officer 
1=Enlisted 
Pre-Gestational 
Diabetes 
0=No ICD-9-CM diagnoses in birth hospitalization record(s) 
1=≥1 ICD-9-CM diagnosis in birth hospitalization record(s) 
Entry to Military 
Before 2001 
0=No 
1= Yes 
Military Branch 
0=Air Force 
1=Army 
2=Navy (includes Marines and Coast Guard) 
Occupation 
0=Other 
1=Combat 
2=Healthcare  
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APPENDIX 3: 
Supplementary Tables for the Results Section 
 
Table 1. Odds-ratio and 95% Confidence Intervals for Deployed vs. Non-Deployed Women, HDP          
Sub-Types.1,2 
  
Chronic 
Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=31,549  n=32,670 n=33,742 n=31,224 
453 cases 1,574 cases 2,646 cases 128 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Deployed 
  Yes vs. No 1.03 0.85-1.25 1.04 0.93-1.16 1.01 0.93-1.10 0.91 0.62-1.32 
Maternal Age at Birth 
  18 to 24 years 1.00 1.00 1.00 1.00 
  25 to 29 years 1.54 1.23-1.94 1.05 0.92-1.19 0.97 0.88-1.08 0.92 0.58-1.47 
  30 to 34 years 1.70 1.21-2.40 1.02 0.83-1.25 1.14 0.97-1.34 1.55 0.84-2.86 
  ≥35 years 4.88 3.40-7.00 1.05 0.77-1.45 1.72 1.38-2.14 2.33 1.07-5.11 
Maternal Race 
  White 1.00 1.00 1.00 1.00 
  Black 1.75 1.42-2.16 0.91 0.80-1.02 1.31 1.20-1.44 1.10 0.73-1.67 
  Hispanic 0.59 0.41-0.85 0.53 0.44-0.63 0.87 0.77-0.99 0.46 0.23-0.93 
  Other3 0.74 0.50-1.09 0.76 0.62-0.91 0.95 0.82-1.10 1.10 0.62-1.97 
Marital Status at Birth 
  Married 1.00 1.00 1.00 1.00 
  Single, never married 0.74 0.59-0.92 0.83 0.74-0.93 1.01 0.93-1.11 0.92 0.61-1.38 
  Other 0.89 0.52-1.53 1.12 0.84-1.50 0.81 0.61-1.05 1.41 0.57-3.50 
Pay Grade at Birth 
  Officer 1.00 1.00 1.00 1.00 
  Enlisted 1.40 1.02-1.93 1.2 0.99-1.45 1.39 1.18-1.63 0.93 0.52-1.66 
Pre-Gestational Diabetes 
  Yes vs. No 3.36 0.78-14.57 2.03 0.61-6.70 2.71 1.18-6.23 No cases 
 
1Women with missing values are not included in regression models. 
2Logistic models are adjusted for all covariates in the table. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
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Table 2. Odds-ratio and 95% Confidence Intervals for Timing of Deployment End Relative to Birth, HDP Sub-Types.1,2 
  
Chronic 
Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=31,056 n=32,154 n=33,220 n=30,731 
448 cases 1,546 cases 2,612 cases 123 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Timing of Deployment Ending Relative to Birth 
  Non-deployed 1.00 1.00 1.00 1.00 
  Ended ≥12 months before birth 1.15 0.92-1.43 1.13 0.99-1.28 0.99 0.89-1.10 0.96 0.62-1.48 
  Ended <12 months before birth 0.86 0.63-1.18 0.87 0.74-1.03 1.07 0.95-1.20 0.62 0.32-1.20 
Maternal Age at Birth 
  18 to 24 years 1.00 1.00 1.00 1.00 
  25 to 29 years 1.52 1.21-1.91 1.04 0.91-1.18 0.97 0.88-1.08 0.91 0.56-1.46 
  30 to 34 years 1.67 1.18-2.36 0.99 0.81-1.23 1.12 0.95-1.32 1.46 0.77-2.76 
  ≥35 years 4.77 3.32-6.87 1.01 0.73-1.40 1.71 1.38-2.14 2.07 0.91-4.72 
Maternal Race 
  White 1.00 1.00 1.00 1.00 
  Black 1.76 1.43-2.16 0.91 0.80-1.03 1.32 1.20-1.45 1.12 0.74-1.71 
  Hispanic 0.58 0.40-0.84 0.54 0.45-0.65 0.86 0.76-0.98 0.49 0.24-0.98 
  Other3 0.72 0.48-1.07 0.75 0.62-0.91 0.94 0.81-1.09 1.07 0.59-1.95 
Marital Status at Birth 
  Married 1.00 1.00 1.00 1.00 
  Single, never married 0.74 0.59-0.92 0.84 0.74-0.94 1.002 0.92-1.09 0.94 0.62-1.41 
  Other 0.84 0.48-1.48 1.07 0.79-1.44 0.82 0.63-1.07 1.52 0.61-3.79 
Pay Grade at Birth 
  Officer 1.00 1.00 1.00 1.00 
  Enlisted 1.43 1.03-1.97 1.18 0.98-1.43 1.39 1.28-1.63 0.89 0.50-1.62 
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Table 2. Odds-ratio and 95% Confidence Intervals for Timing of Deployment End Relative to Birth, HDP Sub-Types 
(Continued).1,2 
 
 
Chronic 
Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=31,056 n=32,154 n=33,220 n=30,731 
448 cases 1,546 cases 2,612 cases 123 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
 
Pre-Gestational Diabetes 
  Yes vs. No 3.31 0.76-14.32 2.01 0.61-6.64 2.73 1.18-6.28 No cases 
 
1Women with missing values for any variable included in a model and those missing from original DOD deployment database or with overlapping 
deployment dates are not included in the regression models. 
2Logistic models are adjusted for all covariates in the table. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
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Table 3. Odds-ratio and 95% Confidence Intervals for Cumulative Weeks of Deployment among Deployed Women 
Only, HDP Sub-Types.1,2 
  
Chronic 
Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=10,255 n=10,612 n=10,975 n=10,134 
158 cases 515 cases 878 cases 37 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Cumulative Weeks of Deployment 
  Each 1 month increase 1.02 0.99-1.06 1.01 0.99-1.03 1.01 0.99-1.02 0.97 0.90-1.05 
Maternal Age at Birth 
  18 to 24 years 1.00 1.00 1.00 1.00 
  25 to 29 years 1.01 0.68-1.49 1.08 0.88-1.33 0.91 0.76-1.07 0.44 0.17-1.16 
  30 to 34 years 1.53 0.88-2.66 1.04 0.74-1.45 1.12 0.86-1.46 1.21 0.40-3.62 
  ≥35 years 3.85 2.05-7.22 1.12 0.66-1.88 1.85 1.29-2.64 1.22 0.28-5.33 
Maternal Race 
  White 1.00 1.00 1.00 1.00 
  Black 2.01 1.40-2.89 0.94 0.76-1.17 1.56 1.33-1.84 2.42 1.12-5.24 
  Hispanic 0.74 0.42-1.31 0.61 0.45-0.81 0.91 0.73-1.14 1.17 0.37-3.68 
  Other3 1.02 0.55-1.90 0.65 0.45-0.93 1.12 0.86-1.44 1.75 0.56-5.41 
Marital Status at Birth 
  Married 1.00 1.00 1.00 1.00 
  Single, never married 0.77 0.54-1.11 0.74 0.60-0.92 0.97 0.83-1.13 1.74 0.83-3.65 
  Other 0.68 0.27-1.70 0.82 0.51-1.33 0.79 0.52-1.19 2.71 0.77-9.56 
Pay Grade at Birth 
  Officer 1.00 1.00 1.00 1.00 
  Enlisted 1.62 0.88-2.96 1.49 1.05-2.11 1.42 1.07-1.90 0.37 0.13-1.11 
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Table 3. Odds-ratio and 95% Confidence Intervals for Cumulative Weeks of Deployment among Deployed Women 
Only, HDP Sub-Types (Continued).1,2 
 
 
Chronic 
Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=10,255 n=10,612 n=10,975 n=10,134 
158 cases 515 cases 878 cases 37 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Branch 
  Air Force 1.00 1.00 1.00 1.00 
  Army 0.83 0.54-1.28 0.86 0.68-1.10 0.85 0.70-1.03 0.52 0.23-1.15 
  Navy4 0.80 0.53-1.22 0.74 0.59-0.94 0.90 0.75-1.08 0.31 0.13-0.78 
Occupation 
  Combat 0.94 0.54-1.64 0.75 0.53-1.05 0.93 0.73-1.18 0.22 0.03-1.68 
  Healthcare 1.03 0.61-1.73 1.48 1.14-1.91 0.98 0.77-1.24 1.64 0.69-3.85 
  Other 1.00 1.00 1.00 1.00 
Pre-Gestational Diabetes 
  Yes vs. No 10.9 1.33-89.72 2.41 0.29-19.79 No cases No cases 
 
1Women with missing values for any variable included in a model and those missing from original DOD deployment database or with 
overlapping deployment dates are not included in the regression models. 
2Logistic models are adjusted for all covariates in the table. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
4Navy includes the Marines and Coast Guard. 
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Table 4. Frequency of Main Exposures and Covariates by HDP Status for PDHA Moms Missing 
PTSD/Probable Responses Only.1 
  
Total HDP No HDP p-value
2 
n=808 n=98 n=710 
12.1% 87.9% 
n % n % n % 
Maternal Age at Birth 
  18 to 24 years 286 35.4 25 8.8 261 91.3 
0.65 
  25 to 29 years 340 42.1 43 12.7 297 87.4 
  30 to 34 years 135 16.7 24 17.8 111 82.2 
  ≥35 years 47 5.8 6 12.8 41 87.2 
Maternal Race 
  White 436 55.4 53 12.2 383 87.8 
<0.0001 
  Black 194 24.7 31 16.0 163 84.0 
  Hispanic 92 11.7 4 4.4 88 95.7 
  Other3 65 8.3 7 10.8 58 89.2 
  Missing 21 2.6 3 14.3 18 85.7   
Marital Status at Birth 
  Married 609 75.7 76 12.5 533 87.5 
0.02   Single, never married 163 20.3 17 10.4 146 90.0 
  Other 33 4.1 4 12.1 29 87.9 
  Missing 3 0.4 1 33.3 2 66.7   
Pay Grade at Birth 
  Officer 124 15.4 21 16.9 103 83.1 
0.07 
  Enlisted 684 84.7 77 11.3 607 88.8 
Pre-Gestational Diabetes 
  Yes 0 0.0         
  
  No 808 100         
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Table 4. Frequency of Main Exposures and Covariates by HDP Status for PDHA Moms Missing 
PTSD/Probable Responses Only (Continued).1 
 
 
Total HDP No HDP p-value
2 
n=808 n=98 n=710 
12.1% 87.9% 
n % n % n % 
Entry to Military Before 2001 
  Yes 129 17.4 83 13.6 529 94.6 
0.01 
  No 612 82.6 7 5.4 122 86.4 
  Missing 67 8.3 8 11.9 59 88.1   
Confirmed PTSD 
  Yes 0 0.0         
  
  No 808 100         
Branch 
  Air Force 555 68.7 70 12.6 485 87.4 
0.01   Army 205 25.4 24 11.7 181 88.3 
  Navy4 48 5.9 4 8.3 44 91.7 
Occupation 
  Combat 82 12.6 6 7.3 76 92.7 
0.11   Healthcare 102 15.7 18 17.7 84 82.4 
  Other 466 71.7 59 12.7 407 87.3 
  Missing 158 19.6 15 9.5 143 90.5   
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Table 4. Frequency of Main Exposures and Covariates by HDP Status for PDHA Moms Missing 
PTSD/Probable Responses Only (Continued).1 
 
 
Total HDP No HDP p-value
2 
n=808 n=98 n=710 
12.1% 87.9% 
n % n % n % 
Deployment Location 
  Kosovo Only 31 4.7 3 9.7 28 90.3 
0.01 
  Southwest Asia Only 1 0.2 0 0 1 100 
  OEF/OIF Only 613 92.0 74 12.1 539 87.9 
  Other5 21 3.2 6 28.6 15 71.4 
  Missing 142 17.6 15 10.6 127 89.4   
1Missing values are not included in calculated percents. 
2P-values are for Chi-square tests of homogeneity (or Fisher exact tests if a cell <5) for categorical variables and t-tests 
for continuous variables using a 5% significance level. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
4Navy included the Marines and Coast Guard. 
5Other included Kosovo and OEF/OIF, Southwest Asia and OEF/OIF. 
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Table 5. Odds-ratio and 95% Confidence Intervals for Any PTSD vs. None, Racial Groups.1,2 
  
White Black Hispanic Other3 
n=18,039 n=9,264 n=5,220 n=3,334  
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Any PTSD4 
  Yes vs. No 1.08 0.84-1.41 1.08 0.74-1.59 1.16 0.65-2.10 1.87 1.05-3.34 
Maternal Age at Birth 
  18 to 24 years 1.00 1.00 1.00 1.00 
  25 to 29 years 1.00 0.90-1.11 1.12 0.97-1.29 1.07 0.85-1.35 1.05 0.81-1.36 
  30 to 34 years 1.05 0.89-1.24 1.43 1.15-1.78 1.01 0.65-1.55 1.21 0.79-1.85 
  ≥35 years 1.60 1.28-1.99 2.00 1.47-2.72 1.42 0.73-2.78 2.19 1.24-3.84 
Marital Status at Birth 
  Married 1.00 1.00 1.00 1.00 
  Single, never married 0.90 0.81-0.99 0.99 0.88-1.11 0.99 0.81-1.21 0.74 0.58-0.95 
  Other 0.97 0.75-1.26 0.98 0.68-1.41 0.91 0.53-1.58 0.60 0.26-1.42 
Pay Grade at Birth 
  Officer 1.00 1.00 1.00 1.00 
  Enlisted 1.27 1.09-1.47 1.34 1.02-1.75 1.08 0.67-1.72 1.35 0.91-2.01 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic models are adjusted for all covariates in the table. 
3Other race includes Asian, American Indian, and DOD "Other" category. 
4Crude OR did not change after adjustment for listed covariates. 
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Table 6. Odds-ratio and 95% Confidence Intervals for Any PTSD and HDP Sub-Types, Entire Cohort.1,2 
  
Chronic Hypertension Gestational Hypertension Preeclampsia Unknown Hypertension 
n=31,549 n=32,670 n=33,742 n=31,224 
453 cases 1,574 cases 2,646 cases 128 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
 
Any PTSD3 
  No 1.00 1.00 1.00 1.00 
  Yes 1.13 0.63-2.01 1.24 0.92-1.68 1.06 0.82-1.38 1.72 0.70-4.22 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic models are adjusted for maternal age at birth, maternal race, marital status at birth, pay grade, and pre-gestational diabetes. 
3Crude OR did not change after adjustment for listed covariates. 
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Table 7. Odds-ratio and 95% Confidence Intervals for PTSD and HDP, 
Case-Definition Based on Screening among PDHRA Moms Only.1,2  
n=3,021 
  Crude OR 95% CI 
Adjusted 
OR 
95% CI 
PTSD (≥3 Case Definition)  
  No PTSD 1.00 1.00 
  Confirmed 1.50 0.81-2.80 1.45 0.77-2.72 
  Probable 1.22 0.79-1.89 1.23 0.79-1.92 
  Possible 0.88 0.26-2.97 0.91 0.27-3.11 
PTSD (≥2 Case Definition)  
  No PTSD 1.00 1.00 
  Confirmed 1.36 0.70-2.65 1.32 0.67-2.59 
  Probable 1.12 0.78-1.60 1.14 0.79-1.63 
  Possible 1.39 0.73-2.64 1.41 0.74-2.69 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic model adjusted for maternal age at birth, maternal race, marital status at 
birth, pay grade at birth, pre-gestational diabetes, branch, and occupation. 
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Table 8. Odds-ratio and 95% Confidence Intervals for PTSD and HDP Sub-types, Case-Definition Based on Screening among 
PDHA Moms Only.1,2 
  
Chronic Hypertension 
Gestational 
Hypertension 
Preeclampsia 
Unknown 
Hypertension 
n=6,369 n= 6,606 n=6,794 n=6,287 
104 cases 341 cases 529 cases 22 cases 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
PTSD (≥3 Case Definition) 
  No convergence     No convergence 
  No PTSD 1.00 1.00 1.00 1.00 
  Confirmed 1.20 1.16-1.23 1.01 0.51-2.01 1.09 0.61-1.95 No cases 
  Probable 0.46 0.45-0.48 1.69 1.04-2.76 1.13 0.71-1.79 1.05 0.14-8.21 
  Possible 0.33 0.29-0.37 2.18 0.65-7.31 0.88 0.21-3.74 No cases 
PTSD (≥2 Case Definition) 
        No convergence 
  No PTSD 1.00 1.00 1.00 1.00 
  Confirmed 1.23 0.38-3.97 1.03 0.51-2.04 1.10 0.62-1.97 No cases 
  Probable 0.88 0.38-2.02 1.58 1.08-2.32 1.18 0.83-1.66 1.94 0.55-6.89 
  Possible No cases 1.33 0.41-4.34 1.08 0.38-3.02 No cases 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic model adjusted for maternal age at birth, maternal race, marital status at birth, pay grade at birth, pre-gestational diabetes, branch, and 
occupation. 
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Table 9. Odds-ratio and 95% Confidence Intervals for Pre-Post Agreement Between 
PDHA and PDHRA PTSD Screening and HDP.1,2 
  
PTSD ≥3 Case 
Definition 
PTSD ≥2 Case 
Definition 
n=2,216 n=2,223 
OR 95% CI OR 95% CI 
PTSD Agreement 
  Both Negative 1.00 1.00 
  Positive Agreement 1.31 0.56-3.06 1.18 0.63-2.20 
  Negative to Positive 1.19 0.65-2.17 1.00 0.61-1.62 
  Positive to Negative 0.96 0.54-1.71 0.97 0.61-1.57 
  Missing on PDHA and/or PDHRA 0.52 0.15-1.81 0.53 0.15-1.83 
 
1Women with missing values for covariates are not included in regression models. 
2Logistic model adjusted for maternal age at birth, maternal race, marital status at birth, pay grade at 
birth, pre-gestational diabetes, branch, and occupation. 
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